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Abstract 
Our objectives were to compare the efficacy and safety between selective laser 
trabeculoplasty (SLT) and argon laser trabeculoplasty (ALT) for the open-angle glaucoma 
patients who had 360-degree SLT previously and to explore the baseline predictors for the 
treatment success. Data were obtained from a multicenter, patient-masked, randomised, 
parallel-group, active-controlled trial. The enrolled patients were randomly assigned to 
receive either SLT or ALT. At 12-month follow-up, the mean intraocular pressure (IOP) 
reduction was 3.35 mmHg and 3.36 mmHg after SLT and ALT respectively. The 
difference of mean IOP reduction was -0.01 mmHg (n=115). The 95% CI of the 
difference was between -1.86 to 1.84 mmHg and was within the predetermined 
equivalence margin (-3 to +3 mmHg). Baseline IOP and number of glaucoma medication 
were significant predictors of treatment success (OR, 1.19 and 0.63). The findings suggest 
that although SLT had an equivalent IOP-lowering effect as ALT after the failure of 360-
degree SLT, repeat laser treatments had a lower efficacy than the primary ones.  
Keywords 
Argon laser trabeculoplasty, equivalence, intraocular pressure, predictor, randomised 
controlled trial, selective laser trabeculoplasty.  
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Chapter 1 Introduction 
 
This chapter includes five sections. Section 1 describes the background knowledge of 
primary open-angle glaucoma, secondary open-angle glaucoma, and ocular hypertension. 
Section 2 explains the rationale for this study. Section 3 constructs the goal and objectives 
of the study. Section 4 presents the data resources and my role in the study. Section 5 
provides an outline of this thesis.  
1.1 Background 
Definition and classification of glaucoma  
Glaucoma is a type of optic neuropathy with characteristic progressive degeneration and 
functional deterioration of the optic nerve, including the retinal nerve fibre layer and optic 
nerve head, leading to visual field loss and even blindness.1 2 Based on the appearance of 
the iridocorneal angle, glaucoma is divided into angle-closure glaucoma (ACG) and open-
angle glaucoma (OAG), both of which can be subdivided into primary or secondary based 
on without or with ocular or systemic causes.3 4 5 In primary open-angle glaucoma 
(POAG), the iridocorneal angle is wide and open (unobstructed) with normal appearance, 
but aqueous outflow is diminished.5 The intraocular pressure of POAG can be high or 
normal.6 Examples of secondary OAG includes pseudoexfoliation syndrome (PXF) 
related glaucoma and pigmentary dispersion syndrome (PDS).5 In this thesis, POAG, PXF 
and PDS were studied. Besides, ocular hypertension (OHT), was also included to 
generalize the study population.   
Epidemiology of POAG 
• Prevalence of glaucoma  
Glaucoma was the first leading cause of irreversible blindness globally in 2002 according 
to the latest data.7 It is estimated that there will be 76 million people with glaucoma in 
2020 and the number will rise to 111 million in 2040 owing to an aging population.8 
POAG will account for around 70% of all types of glaucoma worldwide.8 9 According to 
the self-report surveys described by Perruccio et al., in 2002-2003, it was estimated 
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409,000 Canadians had glaucoma.10  
• Risk factors of POAG 
General risk factors of POAG 
The prevalence and progression of OAG increased with age.11 12 It has been consistently 
found that a higher prevalence of OAG in persons who are African-derived (black).11 A 
family history of OAG, specifically the first-degree relatives (parent, sibling, or child) 
has been confirmed to be a strong risk factor for OAG in several studies.13 
Ocular risk factors of POAG 
Intraocular pressure (IOP) 
The major risk factor for glaucoma is intraocular pressure (IOP).3 Previous prevalence 
surveys and longitudinal studies showed a consistent dose-response relationship between 
IOP and the incidence as well as progression of glaucoma.13 Several randomised 
controlled trials (RCTs) also confirmed IOP-lowering treatments can decrease the 
incidence or progression of glaucoma.14 15 16 
In the Baltimore Eye Survey17, the prevalence of POAG increased with the score of the 
screening IOP.  Compared with eyes which had an IOP lower than 15 mmHg, the relative 
risk was 12.8, 39.0, and 40.1 respectively in eyes which had an IOP between 22 to 29 
mmHg, between 20 to 34 mmHg, and 35 mmHg or above. The results of the Early 
Manifest Glaucoma Trial showed that on average, the estimated risk of the progression of 
OAG decreased by 10% with each 1 mmHg reduction of the baseline IOP.12 
Myopia 
Evidence has shown the association between myopia, especially high myopia, with OAG 
through case series, case-control studies, and large population-based prevalence surveys. 
These have reported the elevation of the prevalence of OAG in people with myopia 
between 48% to 70% after adjusting for age and sex.13 However, The Blue Mountains 
Eye Study found a significant but non clinically meaningful IOP difference (0.45 mmHg) 
between myopic eyes and non-myopic eyes and described that structural and genetic 
characters in myopic eyes may contribute to the association between myopia and 
glaucoma.18 
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Others 
Both the Ocular Hypertension Treatment Study and the Early Manifest Glaucoma Trial 
showed central corneal thickness was a predictor of development and progression of 
OAG.19 20 Exfoliation syndrome was associated with progression of OAG in the Early 
Manifest Glaucoma Trial.20 
Systemic risk factors of POAG 
Blood pressure 
The meta-analysis of Zhao et al. summarised 60 observational studies and identified that 
the positive association between blood pressure and IOP were consistent and robust: on 
average, increasing systolic blood pressure by 10 mmHg increased IOP by 0.26 mmHg 
and increasing diastolic blood pressure by 5 mmHg increased IOP by 0.17 mmHg.21 Low 
blood pressure, by contrast, was shown to be a risk factor for progression of glaucoma in 
the Early Manifest Glaucoma Trial, and the negative association may be due to the 
reduction of ocular perfusion pressure caused by low blood pressure.20 Therefore, it was 
suggested that the relationship between blood pressure and glaucoma is U-shaped.22  
Diabetes 
Although some studies suggested that people with diabetes have a higher risk of OAG, it 
has not been a consistent finding.23  The association might be confounded by IOP.23 
Besides, lack of standard definition of diabetes among articles is another reason for the 
discrepancy in conclusions.23 The Baltimore Eye Survey showed that diabetes patients 
tended to have a higher IOP, but they did not have a greater risk of OAG.24  
Others  
The relationship between cerebrospinal fluid and glaucoma is not well understood. 
Studies have shown that the increase of the pressure difference between IOP and the 
orbital cerebrospinal fluid pressure was a possible risk factor for glaucoma.25 Similar to 
diabetes, evidence of the association between glaucoma and other systemic diseases, such 
as migraine, thyroid disorders, sleep apnea, and cardiovascular disease, is not 
consistent or not sufficient.23  
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Figure 1: Formation and circulation of the aqueous humor. 
 
The diagram shows the anterior segment of the eye. Aqueous humor, produced in the ciliary body, 
circulates through the pupil into the anterior chamber, passes through the trabecular meshwork 
into Schlemm’s canal, and finally, drains into the episcleral venous system.5 Reproduced with 
permission from Kwon, Y. H., Fingert, J. H., Kuehn, M. H. & Alward, W. L. M. Primary open-
angle glaucoma. N. Engl. J. Med. 360, 1113–24 (2009), Copyright Massachusetts Medical 
Society. 
Pathology and mechanism of POAG 
Although the pathogenesis of POAG has not been fully understood, elevated IOP is 
considered an important causative factor of POAG.26 Aqueous humor, which has multiple 
physiologic functions for the eye, is produced at the ciliary body. The most important 
outflow pathway by which the aqueous humor leaves the eye is through the trabecular 
meshwork located at the iridocorneal angle (Figure 1).5 27 IOP is normal when the 
circulation is balanced. For whatever reasons, reduction of aqueous outflow through 
trabecular meshwork elevates IOP.5 27 In OAG, IOP elevation is due to the increased 
resistance of aqueous drainage through the trabecular meshwork.5 28 By contrast, the 
access to the trabecular meshwork outflow pathway is obstructed by the iris in angle-
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closure glaucoma patients.28 Increased IOP causes extra mechanical stress and strain in all 
compartment of the eye, notably the lamina cribrosa (the collagen support tissue of the 
optic nerve) and adjacent tissue, and increases the probability of progressive damage of 
the optic nerve head.2 28  In normal tension open-angle glaucoma, the glaucomatous optic 
neuropathy may be caused by a large pressure gradient across the lamina cribrosa due to 
an abnormally low pressure of cerebrospinal fluid in the optic nerve subarachnoid 
space.28  
Independently or in addition to IOP, other factors may individually or collectively cause 
the loss of retinal ganglion cells followed by the atrophy of the optic nerve fibres. Those 
factors include vascular dysfunction in the retina, autoimmune-mediated nerve damage, 
excessive stimulation of the glutamatergic system, poorly functioning cellular pumps and 
glutamate transporter, oxidative stress and subsequent free radicals formation, some 
inflammatory cytokines, and abnormal immunity.29 30  
Clinical presentation and diagnosis of POAG 
In general, POAG is a chronic, binocular disease.29 The progression between two eyes 
may be asymmetric, with one eye having more adversely affected optic neuropathy than 
the other.29 Due to the asymptomatic nature of POAG, several population-level surveys 
found that up to 50% of people with glaucoma were unaware of the disease until 
recognizable vision loss when they were examined.28 Diagnosis of POAG is made with 
open and normal iridocorneal angle, detection with the excavation of the optic nerve 
head, thinning of the retinal nerve fibre layer, and narrow neuroretinal rim.2  
Darkroom gonioscopy is used to observe the anterior chamber angle to discriminate 
between open-angle and angle-closure glaucoma.2 In either type of glaucoma, the 
neuroretinal rim becomes narrow with concomitant enlargement of the cup.29 The 
assessment of optic nerve head includes subjective and objective ways.31 To gain a 
stereoscopic view, the subjective examination, which is evaluated by an ophthalmologist, 
should be performed at a slit lamp biomicroscope with an indirect lens or contact lens, 
rather than a direct ophthalmoscope.29 Several objective quantitative technics commonly 
used in the medical clinics include scanning laser polarimetry, confocal scanning laser 
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ophthalmoscopy, and optical coherence tomography (OCT).32 OCT is now the most 
commonly used test. An indirect test used is the visual field. 
Diagnosis of POAG does not require visual field loss because it usually happens after the 
damage of the optic nerve head and the retinal nerve fibre layer.5 However, perimetry is 
an important tool for the recording and monitoring the functional decline due to 
glaucoma.2 Similarly, elevated IOP is not a diagnostic requirement of glaucoma.2 Several 
population-based studies found that up to 50% of glaucoma patients had an IOP lower 
than 22 mmHg.28 Since IOP is a major risk factor for glaucoma, it is used to predict the 
progression of glaucoma. Various contact and non-contact tonometers are available for 
IOP test. Goldman applanation tonometry is considered the most widely adopted 
approach.5 
Treatment of POAG 
The goal of POAG treatment is to preserve vision by lowering IOP, which can be 
achieved by glaucoma medication, laser therapy, and surgery.2 33 The five contemporary 
classes of medication in use include prostaglandin analogues (PGAs), beta-blockers 
(BBs), carbonic anhydrase inhibitors (CAIs), alpha-agonists (AAs), and cholinergic.34 
Besides those single topical ocular hypotension agents, some fixed combination therapies 
are available in Canada, including Cosopt (combines a beta-blocker and a CAI), 
Combigan (combines a beta-blocker and an alpha-agonist), DuoTrav (combines a 
prostaglandin analogue and a beta-blocker), and Xalacom (combines a prostaglandin 
analogue and a beta-blocker).35 The most common types of laser treatment for open-angle 
glaucoma are argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty 
(SLT).36 Incisional glaucoma surgery is not considered as the primary treatment in most 
settings due to the potential risks of severe complications.2 
• Glaucoma medication 
Prostaglandin analogues  
The IOP-lowering effect of prostaglandin analogues (PGAs) is achieved by improving 
uveoscleral outflow (the second most important outflow channels after the trabecular 
meshwork).37 The possible mechanisms include relaxation of the ciliary muscle and 
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remodeling extracellular matrix of the ciliary muscle as well as sclera.37 Latanoprost, 
bimatoprost, travoprost, unoprostone, and tafluprost are the five commercially available 
PGAs, and the first three types of PGAs are the most commonly used in clinical 
practice.34 All of them reduce IOP by around 30%.34 The systemic adverse effects are rare 
for PGAs. The common local adverse effects include conjunctival hyperemia, eyelash 
growth, and periorbitopathy.34 38  In general, the PGAs are well tolerated, and less than 
5% of patients discontinue to use them as a result of side effects.39 
Beta-blockers  
Beta-blockers (BBs) have been the mainstay of glaucoma medication for decades since 
their introduction in 1978.34 The mechanism of IOP-lowering effect is suppression of 
aqueous humor production via the blockage of 𝛽-adrenoreceptors in ciliary epithelium 
cells.34 The suppression was observed using fluorophotometry in humans.40 There are two 
types of BBs including nonselective 𝛽1 and 𝛽2 antagonists along with selective 𝛽1 
antagonists.34 The nonselective type includes timolol, levobunolol, metipranolol, and 
carteolol. Betaxolol is a selective 𝛽1 drug. The average IOP reduction effect of timolol is 
20%-30%, and it was considered the gold standard glaucoma drug therapy by the US 
Food and Drug Administration (FDA).39 Systemic adverse effect limited the use of BBs 
in some patients who have severe heart disease, asthma, or chronic obstructive pulmonary 
disease.34 
Carbonic Anhydrase Inhibitors  
Carbonic anhydrase inhibitors (CAIs) reduce IOP by reducing the aqueous humor 
production.39 In the ciliary epithelium, the conversion of CO2 and H2O to HCO3– and 
H+ is an important process for aqueous humor production, and the conversion is catalysed 
by carbonic anhydrase isoenzyme II, the activity of which can be suppressed by CAIs.39 
Both systemic and topical CAIs agents can be used to treat glaucoma. Systemic CAIs 
include acetazolamide and methazolamide. In the study of Dailey et al, acetazolamide 
(250 mg) produced a 21% decrease in IOP.41 Topical CAIs include dorzolamide and 
brinzolamide. Three times daily dorzolamide lowered IOP by 17% to 23%.42 
Paraesthesias of hands and feet, nausea, vomiting, fatigue, and weight loss are common 
when using oral CAIs.39 For long-term users, renal stones may develop.39 Due to the 
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potential systemic complications, oral CAIs is usually reserved for short-term use only, 
such as before surgery. Although some local discomfort may happen such as burning, 
itching, topical CAIs are safe systemically.34 
Alpha-agonists  
Alpha-agonists (AAs) have non-selective forms, which target both 𝛼- and 𝛽-receptors, 
and selective forms, which target only 𝛼-receptors.34 Non-selective AAs include 
epinephrine and dipivefrin, and they reduce IOP by increasing aqueous humor outflow 
via both the trabecular meshwork and uveoscleral pathways.39 Epinephrine reduced IOP 
by 15% to 25%.43 The systemic adverse events of non-selective AAs include headache, 
palpitations, high blood pressure, and anxiety.39  Selective AAs are divided into two 
subtypes: relatively selective 𝛼2-adrenoceptor agonistic with partially 𝛼1-adrenoceptor 
agonistic activity and relatively 𝛼2-adrenoceptor agonistic activity.39 The former one is 
clonidine (not commonly used) and the latter ones include apraclonidine and brimonidine. 
Apraclonidine (𝛼2-adrenoceptor agonist) has been shown to reduce IOP by 20% to 27% 
via reducing aqueous humor formation and increasing outflow through the trabecular 
meshwork pathway.44 45 By contrast, brimonidine has been shown to decrease IOP by 
approximately 24% via reducing humor production and increasing outflow through 
uveoscleral pathway.46 47 Also, brimonidine was found to reduce ganglion cell loss in an 
animal research model and slower rates of visual field progression independently to the 
IOP-lowering effect in an RCT.34 Both the studies suggested a potential neuroprotective 
effect of brimonidine.34 Because of the high rate of allergic blepharoconjunctivitis, 
apraclonidine is seldom used for long term.39 A notable systemic adverse event of 
brimonidine is central nervous system and respiratory suppression due to its significant 
blood-brain barrier cross ability.34 Therefore, it should be avoided in small children.39 
Cholinergic agents  
Cholinergic agents can be divided into direct agonistic agents working directly on 
parasympathetic receptors in the eyes and indirect agonistic agents inhibiting 
acetylcholinesterase.39 Cholinergic agents reduce IOP by increasing aqueous humor 
outflow through the trabecular meshwork pathway.39 Pilocarpine is the most commonly 
used direct agonistic cholinergic agent. It directly stimulates the muscarinic receptors in 
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the ciliary muscle, widens the iridocorneal angle, and results in an increased outflow of 
aqueous humor through the trabecular meshwork.39 Pilocarpine can reduce IOP by 20% 
to 30%.48 Although with rare systemic adverse effects, the local adverse effects of 
pilocarpine are notable, such as diminished visual acuity due to pupillary constriction and 
accommodative spasm, brow ache, and rarely retinal detachment, and those adverse 
effects limit the use of pilocarpine.39 Echothiophate iodide and demecarium bromide are 
the indirect cholinergic agents. The IOP reduction effect of echothiophate is comparable 
to that of pilocarpine.49 Due to the potential prolong respiratory paralysis for general 
anesthesia patients and the cataractogenic effect, the indirect agents are not commonly 
used and restricted only to glaucomas in aphakia or pseudophakia.39 50 51 
Fixed combinations 
According to the Ocular Hypertension Treatment Study, almost 50% of POAG patients 
need two or more medications to achieve the target IOP level (IOP reduced by 20% from 
baseline value with a final IOP less than 24 mmHg).14 Fixed combinations are ideal for 
those patients in terms of increasing patient adherence and persistence with therapy, 
owing to requiring fewer bottles, daily drop instillations, and maybe less cost. 
• Laser treatment  
Argon laser trabeculoplasty  
In 1979, Wise and Witter initially demonstrated the IOP-lowering effect of argon laser 
trabeculoplasty (ALT).52 Shortly after its introduction, ALT has been playing an 
important role in the treatment of uncontrolled open-angle glaucoma for decades.53 In 
ALT, the argon green laser with 488 to 514 nm wavelength, is usually set at a 50-𝜇m spot 
size, 0.1-second duration along with a 300 to 900-mW power, and targets on the 
adjunction between pigmented and non-pigmented trabecular meshwork.36  
Mechanism of ALT 
The possible mechanisms of IOP-lowering effect after ALT include mechanical, biologic, 
and repopulation theory.54 Under the observation with light microscopy, ALT can cause 
crater formation of the trabecular meshwork and collagen whitening which indicates 
coagulative damage.55 Markedly fragmented trabecular meshwork along with disruption 
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of the lumen of Schlemm’s canal has been seen pathologically.56 Those changes may 
increase the outflow of aqueous humor.54 The biomechanical hypothesis suggests that the 
thermal energy after ALT simulates the cellular activity which causes IOP reduction.54 
The cellular changes in the treated trabecular meshwork include recruitment of 
macrophages and increased release of cytokine, both of which can remodel the 
extracellular matrix followed by decreasing aqueous humor outflow resistance and hence 
reducing IOP.54 Repopulation theory suggests that after the damage of ALT, trabecular 
cells have the regenerative ability to maintain a porous and physiologically normal 
extracellular matrix barrier to the outflow of aqueous humor, and subsequently decrease 
IOP.57 
Efficacy of ALT 
On average, ALT reduced baseline IOP by approximately 3.2 to 9.6 mmHg (reduced 12% 
to 35% from baseline IOP) at 1 year,58 59 60 61 62 63 2.8 to 9.8 mmHg (11% to 36%) at 2 
years,58 60 63 and 6.7 to 9.1 mmHg (29% to 34%) at 5 years.60 63 The documented IOP 
response after ALT varied substantially because of the heterogeneity of patient 
characteristics and laser setting. Time to 50% of eyes failure (meandian survival time) 
after ALT was approximately 2 years (success was defined as at least 20% or 3 mmHg 
IOP reduction without additional laser or surgical interventions).58 60  
Adverse events of ALT 
In the Glaucoma Laser Trial, a transient IOP rise of greater than 5 mmHg and 10 mmHg 
were found in 34% eyes and 12% eyes respectively within 4 hours after 180-degree or 
360-degree ALT.64 In that study, among the ALT treated eyes, 46% developed peripheral 
anterior synechiae during the 3-month follow-up.64 Mild iritis after ALT was reported in 
another study.65 
Selective laser trabeculoplasty  
The introduction of selective laser trabeculoplasty (SLT) in 1995 provided a new choice 
for IOP reduction in eyes with OAG or ocular hypertension.66 67 The basic principle of 
SLT is using radiation energy from a 532-nm frequency-doubled Q-switched Nd:YAG 
laser with 400 𝜇m spot size and duration of 3 nanoseconds which targets on the 
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pigmented trabecular meshwork.36 SLT selectively applied on the pigmented cells in 
trabecular meshwork without causing detectable collateral thermal damage.67  
Mechanisms of SLT 
The mechanisms of SLT are not fully understood. In general, similar to ALT, SLT seems 
to increase the outflow via the trabecular meshwork pathway, resulting in IOP 
reduction.67 Findings in the experimental SLT-treated eyes included morphological 
changes in cellular level and biological processes.68 The morphological changes included 
disruption of trabecular endothelial cells, junction disassembly of Schlemm’s canal cells, 
etc.68 69  Besides, a series of biological changes in the anterior segments were identified 
after SLT, such as cytokine secretion, matrix metalloproteinase induction, and monocyte 
migration to the trabecular meshwork.68 69   
Efficacy of SLT 
From the systematic review of Wong et al., the mean IOP reduction after SLT varied 
approximately from 1.4 to 12.0 mmHg, 1.8 to 9.1 mmHg, and 7.4 to 7.9mmHg at post-
laser 1 year,  2 years and 5 years  respectively.70 Accordingly,  the percentage of IOP 
lowering from baseline was 7% to 36%, 8% to 35%, and 32% to 33% at those tree time 
points depending on the difference of baseline IOP, type of glaucoma, and degree of SLT 
treatment, etc.70 Approximately, the median survival time (time of success in 50% eyes) 
was in post-laser 2 years if success was defined as at least 20% or 3 mmHg IOP lowering 
without additional laser or surgical interventions.58 60 71   
Adverse events of SLT 
The adverse events after SLT are mild and rare. Although some discomforts may occur, 
such as redness, pain, and photophobia, they resolve spontaneously within a few days.69 
A transient IOP rise (IOP spike) may happen in 0% to 28% treated eyes with ≥5 mmHg 
increase and in up to 5.5% treated eyes with ≥10 mmHg increase.69 It usually resolves 
within 24 hours with or without glaucoma medication. Peripheral anterior synechiae 
(scarring in the angle) occurred following SLT in 0% to 2.85% eyes according to 9 
previous studies.69 Some isolated case reports of rare adverse events include the 
occurrence of hyphema,72 73 bilateral anterior uveitis,74 and choroidal effusion.75 
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Other types of laser trabeculoplasty 
Micropulse diode laser trabeculoplasty uses an 810-nm diode laser to produce 
micropulse emission of laser energy and to create sublethal thermal damage to the cells in 
the trabecular meshwork.36 Titanium sapphire laser trabeculoplasty uses a 790-nm 
laser which emits flashlamp-pumped, near-infrared energy in pulses which last 5-10𝜇s.36 
The efficacy and safety of those new technics need further evaluations.  
• Glaucoma surgery 
Glaucoma surgery is often conducted when target IOP is not achieved using medical 
and/or laser treatment.3 Incisional glaucoma surgery for the treatment of open-angle 
glaucoma includes filtering surgery and glaucoma drainage-device surgery. The principle 
of the lowering IOP effect of glaucoma surgery is to open the current aqueous humor 
pathways or to create a new pathway to increase aqueous humor outflow.27 
Trabeculectomy is the most common filtering surgery. One study reported a maintenance 
of IOP below 21 mmHg in 57% patients without additional medication 20 years after 
trabeculectomy.76 Complications after trabeculectomy include infection, suprachoroidal 
haemorrhage and low IOP, along with risk of endophthalmitis, and some of them can lead 
to visual impairment.2 Clinical failure of the glaucoma drainage devices was estimated to 
occur at a rate of about 10% per year.77 In the Tube Versus Trabeculectomy Study, the 
overall incidence of postoperative 1-month complications, notably wound leak and 
hyphema, was higher after the trabeculectomy with mitomycin C (incidence of early 
complications, 37%) than after the tube shunt surgery, a type of the drainage-device 
surgery, (incidence of early complications, 21%).78 
SLT versus other glaucoma therapies 
• SLT versus medication 
Several randomised trials have concluded that the IOP-lowering effect did not differ 
between SLT and glaucoma medications. The study conducted by Nagar et al. showed 
that 360-degree SLT did not show a significantly different IOP-lowering effect compared 
with 0.005% latanoprost.79 Another two RCTs compared SLT with topical antiglaucoma 
drugs,  including beta-blockers, brimonidine, pilocarpine, dorzolamide, and latanoprost as 
monotherapy or in combination, and found similar IOP reduction between the two 
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groups.80 81 In terms of treatment compliance, it has been well documented that poor 
adherence is common for glaucoma medication users.82  
• SLT versus ALT 
Regarding efficacy of IOP control, no significant difference was found between ALT and 
SLT in several systematic reviews and meta-analyses.70 83 84 The meta-analysis of Wang 
et al. found SLT produced a higher IOP reduction compared with ALT (weighted mean 
difference, 0.6 mmHg; 95% CI, 0.06 to 1.14 mmHg; p = 0.03).85 Peripheral anterior 
synechiae, which is a laser-related adverse event, have been shown to happen in 12% to 
47% patients after ALT while in less than 2.8% patients after SLT.70 In terms of skill 
requirement, compared with SLT, the spot size of ALT is small, and the procedure 
requires more precise targeting and focusing. Therefore, SLT is easier for general 
ophthalmologists. 
• SLT versus surgery 
According to the RiGOR research, a prospective observational study, the proportion of 
patients, who achieved a 15% IOP reduction in 12 months, was higher in the surgery 
group (trabeculectomy, drainage device procedures, canaloplasty, Trabectome®, 
cyclophotocoagulation or nonpenetrating glaucoma procedures) than the ALT/SLT group 
(87% vs 57%).86 
Secondary open-angle glaucoma 
• Pseudoexfoliative Glaucoma  
Pseudoexfoliative syndrome (PXF) is the most commonly identifiable cause of secondary 
open-angle glaucoma.87 PXF can convert to either angle-closure or open-angle glaucoma 
(pseudoexfoliative glaucoma, PXG) accompanied with the observation of the deposits of 
abnormal fibrillar extracellular white material on almost all the anterior structures of the 
eye.88 The white material is a major risk factor for both the development and progression 
of glaucoma.12 89 The clinical management of PXG is considered to be more difficult than 
POAG partially owing to a higher IOP level, a greater IOP fluctuation, and a higher 
incidence of IOP spike in PXG patients.90 However, patients with PXG have a 
comparable prognosis with POAG after SLT or ALT.91 92 
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• Pigmentary glaucoma  
Pigmentary glaucoma is led by pigment dispersion syndrome (PDS).93 Pigmentary 
glaucoma primarily happens in young, myopic, and male Caucasians.93 The typical 
characters of pigmentary glaucoma include vertical pigment accumulated on the back of 
the cornea (Krukenberg spindle), radial spoke-like transillumination defects in the mid-
peripheral iris, and trabecular meshwork pigmentation.94 The current understanding of the 
IOP elevation is that the overloaded trabecular meshwork endothelial cells die after they 
phagocytose the pigment granules, and the loss of the endothelial cells causes the collapse 
of the trabecular beams resulting in the obstruction of the aqueous humor outflow and the 
following IOP increase.94 Pilocarpine is thought to be the most ideal therapy for 
pigmentary glaucoma because it can reduce the friction between the iris and lens 
zonules.94 However, because of some apparent side effects of pilocarpine, other types of 
glaucoma agents were also applied to pigmentary glaucoma.94 The success rate after SLT 
on pigmentary glaucoma patients did not differ from other types of open-angle glaucoma, 
but it is necessary to reduce laser energy for those with severe pigmented angles.69 
Specifically, several studies have shown ALT was effective particularly in pigmentary 
glaucoma.93 Compared with POAG patients, a higher rate of incisional surgery was 
reported in pigmentary patients to attain a satisfactory IOP control.95 
• Ocular hypertension  
According to the definition from the Guideline Development Group (GDG) in England,96 
ocular hypertension (OHT) is a condition of eyes characterized as IOP > 21 mmHg, open 
drainage angles observed on gonioscopy without glaucomatous optic disc damage, 
detectable nerve fibre layer defect, or visual field loss. In addition, the elevated IOP 
cannot be explained by other causes, such as trauma or uveitis. OHT can accompany with 
pigment dispersion or pseudo-exfoliation. OHT patients are also considered glaucoma 
suspects.97 The Ocular Hypertension Treatment Study reported that at 60-month follow-
up, the cumulative probability of development of POAG was 4.4% in the patients treated 
with glaucoma medications and 9.5% in the patients without treatments (hazard ratio, 0.4; 
95% CI, 0.27 to 0.59;  p<0.001).14 Treatment was recommended to initiate for high-risk 
ocular hypertension patients based on IOP and central corneal thickness (CCT).96 
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Although the GDG guideline suggested the first line treatment was prostaglandin 
analogues (PGAs) or beta-blockers (BBs), some authors found that SLT as the first line 
treatment for OHT not only had a comparable efficacy in lowering IOP with  PGAs but 
also had an advantage of medical adherence and reduced side effects from glaucoma 
medicine.82 96  
1.2 Rationale of the study  
The same with ALT, the efficacy of SLT in IOP reduction may diminish over time.58 60 
After SLT, treatment success (an IOP reduces at least 20% from baseline score) was 
recorded in 66.7%-75% eyes at 6 months, 58%-94% at 12 months, and 11.1%-31% at 5 
years.69 This implies that for the medically uncontrolled patients, up to approximately 
90% of those may need a repeated laser within 5 years after the first SLT to avoid or 
postpone the time for an incisional glaucoma surgery, which may cause more 
complications than laser treatments.  
Except for few crack-like defects of the beams of the trabecular meshwork, the SLT-
targeted tissue has been found intact.55 It provides the theoretical possibility that SLT is 
repeatable. Several studies have demonstrated a comparable effect of IOP reduction 
between initial SLT and repeat SLT no matter after initial 180 or 360-degree trabecular 
meshwork treatment.98 99 100 101 102 103 104 However, most of the studies have noticeably 
methodological limitations. In addition, how many sessions SLT can be repeated has not 
been evaluated.  
Argon laser trabeculoplasty is the first type of laser trabeculoplasty and has been found 
successful in reducing IOP based on level I evidence, which is the highest level of the 
rating scale of evidence-based medicine developed by the Oxford Centre.105 Particularly, 
an RCT comparing ALT and glaucoma medication for the newly diagnosed POAG 
patients showed mean IOP reduction was approximately 9 mmHg for the ALT group and 
7 mmHg for the medication group at 1 year.106 Therefore, ALT was selected as the 
reference laser treatment.  
Three RCTs have shown that the primary SLT and ALT have a comparable IOP-lowering 
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effect.70 84 85 The choice of equivalence study design was based on the hypothesis that the 
equivalent efficacy of SLT and ALT also holds for previous SLT-treated patients and the 
facts that some features of SLT make it outweighs ALT, such as less peripheral anterior 
synechiae and simpler operation skill. 
1.3 Goal and objectives  
The goal of the study was to evaluate whether SLT is repeatable and if so whether SLT 
and ALT have an equivalent efficacy after the failure of the initial SLT.  
Primary objective:  
Currently, IOP is the only modifiable causative factor for glaucoma.5 Furthermore, the 
aim of either SLT or ALT is to reduce IOP. Therefore, the primary objective of the study 
was to test whether SLT has an equivalent IOP reduction effect from baseline to 12 
months compared with ALT. To generalize the study outcome, data from POAG, PXF, 
PDS, OHT patients were included.  
Secondary objectives: 
• To compare the efficacy and safety of SLT and ALT at multiple follow-up time 
points. 
• As described in Section 1.1, approximately 50% patients failed to reach a 20% or 
3-mmHg IOP reduction at 2 years after either SLT or ALT. 58 60 71  It indicates individuals 
have various response to the laser treatment. Many studies have identified baseline IOP as 
the positive predictor for laser treatment success.67 69 107 However, the outcomes of the 
predictive ability of some other predictors are controversial.108 Hence, it is necessary to 
explore the predictors of treatment success after laser trabeculoplasty as one of the 
secondary objectives in this thesis.  
1.4 Data resources and role of the author 
To answer the research questions, data were obtained from an ongoing multicentre RCT, 
which is an equivalence study design. The trial was registered in ClinicalTrials.gov on 
September 11, 2012 (registry number: NCT01687465) with a title of “A randomized 
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clinical trial of selective laser trabeculoplasty (SLT) in open-angle glaucoma who had 
been previously treated with complete SLT” and an acronym of “Repeat Laser Study”. 
Patients with POAG, PXF, PDS, and OHT who had received 360-degree SLT were 
recruited. Because of uncontrolled IOP with medicine and previous SLT, they had been 
scheduled laser treatment and were randomly allocated to receive either SLT or ALT. The 
length of the follow-up time after the laser treatment is 12 months. My role is to analyse 
the data from this ongoing RCT without involving in any study design or site work of this 
RCT.  
1.5 Contents of each chapter 
There are five chapters in this thesis, including the introduction in Chapter 1. Chapter 2 
contains the literature review and summarises studies comparing SLT and ALT with an 
RCT design, evaluating repeat SLT, and exploring factors predicting the success of laser 
trabeculoplasty. Chapter 3 describes the data characteristics and the analysis methods. 
Chapter 4 provides the results of the data analyses. Chapter 5 interprets the study 
outcomes, analyses the strengths and limitations of the thesis, makes a conclusion of the 
thesis work, and proposes future studies about repeat SLT treatment. 
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Chapter 2 Literature Review 
 
There are four sections in this chapter. Section 2.1 summarises the randomised controlled 
trials comparing selective laser trabeculoplasty (SLT) and argon laser trabeculoplasty 
(ALT). Studies about repeated SLT are reviewed in Section 2.2. Section 2.3 describes the 
predictors of laser trabeculoplasty efficacy evaluated in previous studies. A summary of 
this chapter is provided in Section 2.4.  
2.1 RCTs comparing SLT and ALT 
Several randomised clinical trials have been published to compare the efficacy and safety 
between SLT and ALT in the last a decade or so. These are RCTs that look at first laser 
use, but not repeatability. 
Damji et al.109 presented an RCT comparing IOP-lowering effect between SLT and ALT 
with 6-month follow-up. Patients were treated with either standard 180-degree SLT or 
180-degree ALT. Eighteen eyes were treated in each group. Diagnoses included POAG, 
PXF, PDS, OAG status post peripheral laser iridotomy, and Aphakic glaucoma for 19, 10, 
3, 3, and 1 eye respectively. The authors found during the observation period, the two 
groups had a comparable IOP reduction effect, with a mean ± SD of 4.8 ± 3.4 mmHg in 
the SLT group and 4.7 ± 3.3 mmHg in the ALT group. Furthermore, in the patients with 
previously failed ALT treatment, SLT (7 eyes) showed a better outcome in the reduction 
of IOP than ALT (8 eyes) (6.8 ± 2.4 mmHg versus 3.6 ± 1.8 mmHg, p = 0 .01).  
In another RCT also conducted by Damji et al.61 with 1-year follow-up, more patients 
were recruited. There were 176 eyes from 152 patients enrolled in the study, with 102 
having POAG, 52 of PXF, 12 of PDS, 4 of combined mechanisms, and 5 with other 
diagnoses. The surgical parameters were the same as those published in 1999. Both the 
mean ± SD IOP reduction (5.86 ± 6.15 mmHg versus 6.04 ± 4.82 mmHg) and Kaplan–
Meier survival analysis in laser success were not significantly different between the SLT 
group (73 eyes) and the ALT group (74 eyes). Among the SLT subgroup, those eyes 
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treated previously with 360-degree  ALT had a significantly greater mean IOP-lowering 
effect (7.1 mmHg) than those treated with 180-degree ALT (4.8 mmHg), or those without 
previous ALT treatment (5.7 mmHg). In the ALT group, the eyes which had a previous 
180-degree  ALT treatment showed a significantly greater mean IOP reduction (7.0 
mmHg) than those had a previous 360-degree  ALT treatment (4.5 mmHg) or no treatment 
(6.0 mmHg). In the eyes diagnosed as PXF, mean IOP was reduced by 5.7 mmHg in the 
SLT group (n=16) and by 5.4 mmHg in the ALT group (n=23), which had a similar 
outcome with the overall group.  
Later, the same research group60 reported a series of follow-up outcomes from the 
previous patient cohort up to 5 years. The follow-up was completed for 150 eyes at 2 
years, 142 eyes at 3 years, 134 eyes at 4 years, and 120 eyes at 5 years. The numbers of 
eyes in each group at any time point were not significantly different. The results showed 
that there was no significant difference between the SLT and ALT group regarding IOP 
reduction from baseline to 2, 3, 4, or 5-year follow-up time point. Also, the surgical 
success rate was comparable between the two groups during the 5-year observation 
period. IOP decreased by 7.4 ± 7.3 mmHg (mean ± SD) in the SLT group (n=64) and 6.7 
± 6.6 mmHg in the ALT group (n=56) at 5-year post-laser check-up. 
Martinez-de-la-Casa et al110 reported an RCT comparing the efficacy of IOP reduction 
between the 180-degree  SLT and 180-degree  ALT. All the patients were open-angle 
glaucoma (OAG) without PXF or PDS and were poorly medically controlled with 
IOP >21 mmHg. Both of the treatment groups included 20 eyes from 20 patients. At 6-
month post-treatment visit, the mean percentage IOP decreased by 22.2% in the SLT 
group and 19.5% in the ALT group (p = 0.741). Absolute IOP reduction value was not 
reported in the study.  
Best et al.111 conducted an RCT using two different laser systems (Otello and Selecta II) 
for the 360-degree SLT treatment to compare the IOP reduction effect with the 360-degree 
ALT treatment for OHT or OAG patients. In total, two-year follow-up data were available 
for 106 eyes in the Otello SLT group, 110 eyes in the Selecta SLT group, and 32 eyes in 
the ALT group. The mean IOP reduction for those three groups was 1.7 mmHg, 1.8 
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mmHg, and 2.1 mmHg respectively at the 1-year follow-up, and it was 1.7 mmHg, 1.7 
mmHg, and 2.0 mmHg respectively at the 2-year follow-up. However, the authors did not 
report the statistical comparison of the difference among the three groups.83 
Birt et al.62 reported an RCT in 2007. All the patients had a diagnosis of POAG, PXF, or 
PDS. Twenty-seven patients who were given 360-degree ALT previously were assigned to 
180-degree SLT treatment directly. The rest of the participants without SLT or ALT 
treatment history were randomly assigned to 180-degree SLT treatment group (n = 30) or 
180-degree ALT treatment group (n = 39). Mean percentage of IOP reduction was 
significant at 1 year for all the three groups with 23.0% (SD 3.8%) in the SLT group, 
19.3% (SD 4.5%)  in the SLT after ALT group, and 24.1% (SD 2.5%) in the ALT group 
respectively. The difference among the groups was not significant. Furthermore, the study 
showed that the number of medication used at one year significantly reduced in both the 
SLT only group and the SLT after ALT group, but not in the ALT only group. Absolute 
IOP reduction values were not provided in the paper.  
Russo et al.112 performed an RCT comparing the IOP reduction effect between the 360-
degree SLT and the 360-degree ALT on POAG patients. A total of 120 eyes of 120 
patients were recruited with 60 eyes in each group. After the initial treatment, 36 patients 
with IOP > 20 mmHg at 3 months after the laser treatments were retreated randomly with 
another 360-degree SLT or 360-degree ALT and included as Group B. The rest of the 
patients were included in Group A. In Group A, there were 43 eyes underwent SLT and 41 
eyes underwent ALT. The mean IOP reduction at 12 months was 6.01 mmHg in the SLT 
group and 6.12 mmHg in the ALT group (p = 0.794). No significant difference was found 
between the two treatment groups. In Group B, at 12-month follow-up, patients treated 
with repeat SLT showed a significant difference of mean IOP reduction compared with 
repeat ALT (6.24 mmHg versus 4.65 mmHg, p < 0.01). The results suggested that SLT 
was more effective than ALT regarding IOP reduction in patients with previous laser 
history. However, the initial and secondary SLT or ALT allocation can lead to four 
combinations, namely repeat SLT after ALT or SLT and repeat ALT after ALT or SLT. 
Therefore, the outcome of the comparison of the efficacy between repeat SLT and repeat 
ALT can be confounded by the type of the previous laser.  
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Liu et al58 reported an RCT in comparison of SLT and ALT with final IOP among patients 
who were 60 or less. One eye from 42 patients was randomised to receive 180-degree 
SLT (20 eyes) or 180-degree ALT treatment (22 eyes). All the patients were not treated 
with any laser trabeculoplasty before randomisation. The glaucoma type included POAG 
(19), juvenile open-angle glaucoma (10), OHT (8), PXF (2), mixed mechanism glaucoma 
(1), low-tension glaucoma (1), and PDS (1). At 1-year follow-up, the mean ± SD post-
laser IOP was 15.4 ± 3.9mmHg in the SLT group and 19.2 ± 4.9mmHg in the ALT group 
with a significant difference (p=0.03). At 2-year follow-up, the mean ± SD post-laser IOP 
was 17.3 ± 3.7mmHg and 19.1 ± 5.7mmHg in the SLT and ALT group respectively 
without significant difference (p>0.05). The mean IOP reduction was 3.7 and 1.8 mmHg 
in the first and second year after SLT, and it was 2.7 and 2.8 mmHg in the first and second 
year after ALT. IOP increased in the second year in the SLT group was considered that the 
effect of SLT diminished with time.  
Rosenfeld et al.113 conducted an RCT comparing the IOP-lowering effect of SLT with 
ALT targeting only pseudophakic patients (patients with previous cataract surgery). Fifty-
two eyes from 52 patients with POAG, OHT, PXF, or PDS were randomly allocated to 
either the 180-degree SLT or 180-degree ALT treatment group. Those patients who 
needed to either modify the type or number of the IOP-lowering medicine, undergo a 
trabeculectomy, or repeat ALT treatment were excluded from the analyses. It led to 19 
eyes in the SLT group and 18 eyes in the ALT groups included in the final analyses. In 
those 37 patients, the baseline IOP was comparable between the two groups. At the 12-
month check-up, the mean IOP reduction was 4.3 mmHg and 3.23 mmHg in the SLT and 
ALT group respectively without a significant difference ( p = 0.269). This study 
generalized the comparison of efficacy between SLT and ALT to previous cataract surgery 
patients and used the single eye per patient in the analyses. However, the sample size is 
relatively small. 
Popiela et al.114 studied the IOP-lowering effect of 180-degree SLT in comparison with 
180-degree ALT. Patients who had OAG with deteriorated visual field under maximal 
tolerated medical therapy were recruited. In total, 27 patients were included with 21 
diagnosed as POAG, 3 normal pressure glaucoma, 1 PDS, 1 PXF, and 1 juvenile 
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glaucoma. One eye of each participant was randomly selected to receive SLT treatment 
and the other one received ALT treatment. At the final check-up (post-laser 3 months), the 
mean ± SD IOP reduction from baseline was 2.58 ± 4.62 mmHg in the SLT group and 
2.63 ± 3.6 mmHg in the ALT group, and the difference between the two groups was not 
significant (p = 0.84).83  
Kent et al.115 reported a multicentre RCT comparing SLT and ALT in the efficacy of IOP 
reduction in PXF patients. In total, 76 eyes from 60 patients were recruited from 5 
Canadian academic hospitals. Eyes were randomly allocated to either 180-degree SLT 
treatment group (31 eyes) or 180-degree ALT treatment group (45 eyes). Data at 6 months 
was available in 63 eyes. At 6-month follow-up, the IOP reduced by 6.8 ± 5.4 mmHg 
(mean ± SD) in the SLT group and 7.7 ± 7.12 mmHg in the ALT group with a non-
significant difference (p = 0.56).  
Wang et al.84 synthesized the results from 6 RCTs58 60 113 110 62 115 comparing SLT and 
ALT in OAG patients with meta-analysis. The types of OAG included POAG, PXF, and 
mixed. Patients were treated with either 180-degree SLT or 180-degree ALT. The pooled 
result of 4 studies showed the difference of IOP reduction between the two treatments was 
significant at post-treatment 3 months. It favoured SLT with a weighted mean difference 
(WMD) of 1.19 mmHg (95% CI 0.41 to 1.97 mmHg, I2 = 0%, p=0.003). The two 
treatments were identical at 1hour, 1week, 1month, 6 months, and 1 year in terms of IOP 
reduction according to the pooled results of the 6 studies. Furthermore, the author 
conducted a subgroup analysis for patients who were naïve to laser. In this subgroup, the 
author did not find a significant difference between SLT and ALT at 1 year based on 3 
studies. Similarly, in the subgroup for patients who had previously received either SLT or 
ALT treatment, the IOP reduction at 6 months was comparable between the two 
treatments with a WMD of 1.92 mmHg (95% CI -0.91 to 4.74 mmHg, I2 = 77.3%, 
p=0.18). In addition, the pooled result from four studies showed SLT reduced more 
glaucoma medication use than ALT by 0.57 mmHg (95% CI 0.00 to 1.14; p=0.05). The 
success rate of SLT versus ALT was not significantly different with RR = 1.03 (95% CI 
0.83 to 1.28) from 3 studies with various definitions of success. Two studies reported the 
anterior inflammation after laser, the results were contradicted and lacked a uniform 
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standard of inflammation measurement. One study analysed the incidence of IOP spike 
and did not find a difference between the two treatments.  
Wong et al.70 did another meta-analysis including 4 RCTs58 60 113 115 to compare SLT with 
ALT. The difference of absolute IOP reduction at 6 months to 5 years in pooled mean was 
0.5 mmHg (95% CI, -1.5 to 0.4 mmHg) comparing SLT and ALT with fixed effect model 
(I2 = 0). Similarly, the treatment success rate was comparable between SLT and ALT (OR 
= 1.2; 95% CI, 0.7 to 1.8). In terms of reducing number of glaucoma medication, the 
pooled difference between SLT and ALT was 0.2 (95% CI, 0.5 to -0.08) from two RCTs.58 
60 
Wang et al.85 reported a systematic review and meta-analysis synthesizing the information 
from 6 RCTs.58 116 61 110 62 112 The primary outcome was IOP reduction from baseline to 
post-treatment 6 to 24 months. The difference in IOP reduction of SLT versus ALT was 
significant with a WMD of 0.60 mmHg (95% CI, 0.06 to 1.14 mmHg; p = 0.03) and an I2 
of 31%. One of the secondary outcomes was therapeutic IOP response, which was defined 
as IOP-lowering ≥ 3 mmHg and/or > 20% from baseline. The relative risk (RR) of 
therapeutic IOP response was comparable with the two lasers, which was 0.84 (95% CI, 
0.61 to 1.38; p = 0.05). One of the limitations of this review is the information bias. First, 
it included the study of Júnior et al. as an RCT, but the study was reported as a 
prospective, nonrandomised interventional study.116 Second, the author stated that the 
patients in Group B was naïve to laser from the study of Russo et al., and it is not correct 
since those patients were described as having either SLT or ALT treatment previously in 
the literature.112 Furthermore, using the data from the Group B to run a meta-analysis 
should be cautious because the outcomes may be biased owing to the variation of type of 
the initial laser treatment.  
In summary, SLT showed a comparable efficacy with ALT regarding IOP reduction for 
OAG patients in a number of the RCTs and three meta-analyses. The subgroup analyses 
showed SLT might superior to ALT in patients who had received either SLT or ALT laser 
treatment before.109 113  However, because of the imperfect study design and the small 
sample size in those subgroup analyses, further investigations are needed. 
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2.2 Repeat SLT 
Some noticeable structural changes of the trabecular meshwork after the application of 
ALT have been observed pathologically. The typical change was crater formation 
surrounded by coagulative damages.55 Some authors have described a markedly 
decreased efficacy of the repeat ALT compared with the primary ALT.117 118 Those 
outcomes suggest that structural changes of the trabecular meshwork caused by ALT can 
lower the efficacy of the next ALT. 
By contrast, SLT does not cause scarring or contraction of the targeted tissue.54 
Theoretically, it allows the treatment to be repeated. Several studies have evaluated the 
efficacy and safety between the primary and repeat SLT. 
Hong et al.101 reported the efficacy of repeat SLT after the failure of the initial 360-degree 
SLT treatment. The author conducted a retrospective chart review, which included 44 
eyes of 35 patients with POAG, PXF, or PDS. Those patients had the IOP controlled 
successfully for at least 6 months after the first 360-degree SLT treatment and received a 
second 360-degree SLT treatment (102 shots on average). Twenty eyes repeated the SLT 
at 6 to 12 months after the first one, and 24 eyes repeated the treatment at equal or over 
12 months after the initial one. The IOP reduction was significantly greater for the first 
SLT than the second one during the 1 to 3-month follow-up, with an average value of 5 
mmHg for the SLT1 and 2.9 mmHg for the SLT2 (p = 0.01). However, the IOP-lowering 
effect within 5 to 8 months after the SLT treatment was not significantly different 
between SLT1 and SLT 2 (mean IOP reduction, -4 mmHg vs -2.9 mmHg). The authors 
also compared the early repeated (6-12 months) and the late repeated (≥12 months) SLT 
treatment effect and found no significant difference of IOP change during 1 to 4-week, 1 
to 3-month, 5 to 8-month, or 15 to 21-month follow-up.  Also, no uveitis was documented 
in the second SLT. IOP spike was observed in one eye after both the first and the second 
SLT.  The limitation of this study includes baseline IOP being measured three times 
before the first SLT but being measured only one time before the second one. The single 
examination of baseline IOP before the second SLT may introduce measurement bias.  
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Avery et al.100 conducted another retrospective chart review evaluating the efficacy of 
repeat SLT. The study included 42 eyes from 42 patients who had POAG and excluded 
those with PXF or PDS. Nine of the 42 eyes received a third SLT treatment. All the three 
procedures were performed on 360-degree trabecular meshwork with 40-50 shots. On 
average, IOP decreased by 3.6 ± 4.8 mmHg (SD), 4.5 ± 4.5 mmHg, and 3.6 ± 2.9 mmHg 
at 3 to 4 months after the first, second, and third SLT treatment respectively. No 
significant difference was found between the first and the second treatment. In terms of 
duration of success, the author compared the first and the second SLT treatment in 28 
eyes, and found the median survival time was 3 months for the first SLT versus 11 
months for the second SLT (hazard ratio = 0.43; 95% CI, 0.27 to 0.69; p < 0.01). It 
suggested that the effect of repeat SLT treatment for POAG patients may last longer than 
that of the initial treatment. Some limitations of this research should be considered. First, 
the sample size is relatively small and makes the outcome of survival analysis less 
accurate. Second, how the baseline IOP was measured and the comparison of 
complication between the first and the second SLT treatments were not reported.  
Khouri et al.99 retrospectively reviewed the electronic medical records from 45 eyes of 25 
subjects, who underwent two 360-degree SLT treatments. The mean ± SD interval 
between the first and the second SLT was 27 ± 12 months. The follow-up time was up to 
24 months. The baseline IOP was comparable for the two SLT treatments. The mean ± 
SD of IOP change peaked at 4 months (4.6 ± 2.5 mmHg for the first SLT and 3.9 ± 6.3 
mmHg for the second SLT) and reached the lowest at 24 months (2.8 ± 3.4 mmHg for the 
first SLT and 2.7 ± 5.5 mmHg for the second SLT) in both the two SLT treatments. At 12 
months, the mean ± SD IOP reduction was 3.8 ± 3.5 mmHg and 2.9 ± 5.8 mmHg after 
the first and the second SLT treatment. Except at 4, 8, and 12 months, where the initial 
SLT yielded a significantly greater IOP reduction than the repeated one, the effect was 
identical at  1, 18, and 24 months. At 24 months, 8 of 28 (29%) and 11 of 28 (39%) 
versus 10 of 28 (36%) and 15 of 28 (54%) of eyes achieved an IOP reduction ≥20% and 
≥15% after the second versus the first SLT (p > 0.05). No IOP spike was observed in 
either SLT treatment. The study had the advantage of baseline IOP measurement methods 
being the same for the two SLT treatments. One of the limitations is that two eyes of 
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some patients were included in the analyses. Treating the two eyes in one person as 
independent subjects and ignoring the correlation between the two eyes may falsely 
produce a precise confidence interval and a small p value (increase type I error).119 120  
Ayala et al.98 reported a prospective RCT for evaluating the IOP-lowering effect of repeat 
SLT. Patients who had previous inferior 180-degree SLT and needed to receive a second 
SLT were recruited. Each patient was randomly allocated to receive another 180-degree 
SLT either at the same trabecular meshwork area or the untreated trabecular meshwork 
area. The average time interval between two SLT treatments was 12.9 months. The 
patients were diagnosed as POAG or PXF. A total of 80 eyes from 80 patients (40 eyes in 
each group) were included in the analyses. No loss-to-follow-up was documented. IOP 
reduction at post-laser 2h, 1, 3, or 6 months were not significantly different between the 
primary and repeat SLT groups (ANOVA, p=0.137). At 1 month, the mean IOP reduction 
was 5 mmHg in both groups. The authors did not report the scale of IOP change at the 
other time points. Anterior chamber inflammation was similar for each group, and no IOP 
spike (an IOP goes up > 6 mmHg from baseline) was detected at each check-up. 
Noticeably, PXF was diagnosed in 62.5% of all the patients.  
Polat et al.121 conducted a retrospective chart review to explore the IOP-lowering effect of 
repeated 360-degree SLT. There were 38 eyes of 38 participants who were diagnosed as 
POAG, PXF, or PDS in the study. The mean IOP reduction at each time point throughout 
the 24-month follow-up ranged from 2.9 to 5.7 mmHg for the initial SLT and 2.3 to 4.4 
mmHg for the repeat SLT without significant difference between the two SLTs. Kaplan-
Meier survival analysis showed the median survival time was 19 months and 35 months 
for the first and second SLT, respectively if success is defined as no addition IOP-
lowering medications, laser treatments, or incisional glaucoma surgeries. In addition, the 
median duration of IOP lowering ≥ 20% from baseline was 9 months for the first SLT 
and 12 months for the second SLT. No IOP spike nor severe inflammation was noticed 
for both SLTs. One of the advantages of this study is that only one eye per patient was 
included in the analyses. It can avoid the consideration of cluster effect in the outcome 
analyses.  
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Durr et al.103 reported a retrospective chart review evaluating the effect of 360-degree 
SLT on IOP control. Thirty-eight independent eyes who had POAG, normal tension 
glaucoma, or PXF were included in the study. Five patients were lost to follow-up after 
the first SLT, and another 5 patients were lost to follow-up after the second SLT during 
the 15-month study period. IOP reduced 1.8 ± 3.2 mmHg (mean ± SD) and 2.2 ± 3.7 
mmHg at 15 months after the first and the second SLT, respectively. No significant 
difference was found during the 1, 6, and 15-month post-laser treatment time point 
comparing the two SLTs in IOP-lowering magnitude with ANOVA analysis (p=0.53).  
In summary, according to the available information, repeat SLT is comparable to primary 
SLT regarding IOP reduction. Either IOP spike or post-laser inflammation is rare. 
However, only one study is an RCT design, and the others are all retrospective chart 
review. The sample size of most of the previous studies is moderate. Therefore, more 
studies with better study design for evaluating the efficacy of repeat SLT are needed.   
To our best knowledge, no research has been reported comparing SLT and ALT after the 
initial SLT treatment.  
2.3 Predictors of the IOP-lowering effect of laser 
trabeculoplasty 
Baseline IOP 
Higher baseline IOP or pre-laser IOP was found to significantly predict better outcomes 
after ALT or SLT in a large number of studies. The positive correlation was identified 
both in IOP reduction or treatment success with univariate as well as multivariate 
analysis. 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 In contrast, Odberg et al. and 
Elsås et al. found higher baseline IOP to be a significant predictor for ALT treatment 
failure.138 139  
SLT Success of fellow eye 
Regarding the correlation of two eyes in SLT response, Lee et al.140 performed a 
prospective cohort study evaluating the correlation of IOP between paired eyes after 
bilateral SLT. Both eyes of 42 patients with POAG or normal tension glaucoma. The IOP 
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reduction was highly correlated between the paired eyes at post-laser 1day, 1week, and 
1month (Spearman r = 0.7 to 0.9; p < 0.0001). Among those patients, 42.9% had bilateral 
success and 38.1% had bilateral non-success. The rest of the paired eyes (19%) had a 
contradicted outcome. Similarly, the retrospective medical record review of Shazly et al. 
found that the percentage of IOP reduction for the first eye and the fellow eye was highly 
correlated.141 
Aqueous humor dynamics  
Recently, Gulati et al.142 were the first to evaluate the association between aqueous humor 
dynamics and SLT response. They found higher aqueous flow, lower outflow facility, and 
lower uvescleral outflow at baseline significantly predicted a greater IOP reduction after 
SLT. These variables are not easy to record clinically and are not part of typical clinical 
care.  
Factors not correlated with the IOP-lowering effect of laser trabeculoplasty 
Gender,122 131 132 134 136 race,130 135 142 spherical equivalent,122 126 lens status,122 126 131 143 
144 anterior chamber angle grade,131 retinal nerve fibre layer thickness,126 type of 
glaucoma,123 131 134 136 glaucoma duration,122 some glaucoma risk factors (hypertension, 
myopia, family history of OAG),131 132 136 previous ALT,131 134 136 145 and washout of 
glaucoma eye drops134 have not been shown as the significant predictors for SLT or ALT 
success.  
Specifically, Seymenoğlu et al.144 reviewed the history of patients who had either phakic 
or pseudophakic eye status (no previous cataract surgery vs previous uncomplicated 
cataract surgery with implantation of posterior chamber intraocular lens) and received 
3600 SLT. In total, 88 eyes from 88 patients were included. The outcome after SLT was 
comparable between phakic and pseudophakic eyes regarding absolute IOP reduction, 
laser success rate, and percentage IOP reduction up to 12-month follow-up.    
Also, post-laser treatment medication (nonsteroidal anti-inflammatory drugs versus 
steroid) did not show a significant correlation with SLT success.134 146  
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Contradicting predictors of the IOP-lowering effect of laser trabeculoplasty among 
different studies 
Age 
Age was found to have no predictive value for laser success in most of the studies.123 131 
132 134 136 However, Ayala et al. found that older patients were more likely to fail 
earlier.129 
Diabetes 
Both the studies of Koucheki et al.147 and Gracner et al.148 found non-diabetic patients had 
less IOP reduction or treatment success rate after SLT. By contrast, the correlation was 
not found in several other studies.127 135 136 149  
Maximum IOP 
Mao et al.134 found maximum IOP was an independent predictor for SLT success with an 
adjusted OR of 0.9 (95% CI, 0.9 to 1.0; p = 0.0221), which meant higher maximum IOP 
tended to have a lower success rate. The result is contrary to that in the study of Martow 
et al., who found the highest ever recorded maximum IOP was not associated with SLT 
success.131 
Central corneal thickness  
Shazly et al.150 conducted a retrospective chart review for consecutive patients who 
underwent SLT. The baseline IOP was comparable between the two groups of patients 
with different central corneal thickness (CCT). Using an independent sample t-test, the 
authors found that patients with central corneal thickness (CCT) <555 𝜇m had a greater 
mean percentage of IOP reduction compared to those with CCT ≥ 555 𝜇m during the 30-
month follow-up period. However, the conclusion contradicts those from other studies, in 
which an association between CCT and SLT success was not found.122 123 126 131 Studies 
have shown that thinner central corneal thickness (CCT) independently predicted the 
development and progression of open-angle glaucoma.19 20 151 152 Those findings may 
suggest that CCT could indicate some biomechanical or historical characteristics of 
eyes.152 Therefore, it is reasonable to keep exploring the association between CCT and 
laser treatment effect in our study.  
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Trabecular meshwork Pigmentation, Exfoliation  
In the study of Chen et al.,145 trabecular meshwork pigmentation showed a positive effect 
of IOP reduction at post-SLT 7 months, and the interaction effect with exfoliation was 
also significant at this time point. The positive correlation between the scale of trabecular 
meshwork pigmentation and degree of IOP decrease after SLT was also found in the 
study of Wasyluk et al.153 This positive correlation was also identified after ALT 
treatment.139 Nonetheless, Gracner et al. found a negative correlation between the grade 
of trabecular meshwork pigmentation and successful SLT.148 Furthermore, other studies 
did not find a predictable effect of trabecular meshwork pigmentation on SLT success.131 
134 136 146 It is known that pigmented cells in the trabecular meshwork have a greater 
optical absorbance to the laser than the adjacent cells, and this feature provides the 
possibility that SLT can selectively target on the pigmentation cells.83 Hence, the degree 
of pigmentation of trabecular meshwork is likely to be correlated with the effect of SLT. 
Furthermore, ALT was found particularly effective in pigmented glaucoma in several 
studies.93 Therefore, it is necessary to evaluate whether the degree of pigmentation of 
trabecular meshwork can predict the success of laser treatment in our study.  
Visual field 
Two studies found pretreatment visual field defect predicted ALT treatment failure.138 139 
Odberg et al. found the stage of visual field defect (1 to 5 stages) predicted ALT treatment 
failure with RR = 2.1 (95% CI, 1.2 to 3.6; p = 0.01) with COX regression analysis.139 By 
contrast, visual field index was not found to be significantly associated with SLT 
treatment success in another two studies.123 126  
Laser parameter 
Nagar et al. found success rate was greater for patients who received 180-degree or 360-
degree SLT than those received 90-degree SLT.79 Higher energy level within 214.6 to 
234.9 mJ was found to be associated with more IOP reduction after SLT.154 Similarly, 
Habib et al.155 and Ayala et al.129 found higher laser energy predicted a longer time to 
failure after the SLT treatment. However, regarding ALT treatment, Grayson et al. found 
a significantly longer time to failure with 50 burns on 180-degree trabecular meshwork 
compared to 100 burns on 360-degree trabecular meshwork, which suggested lower 
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energy for better outcomes.156 Many other studies, by contrast, did not find a significant 
correlation between laser parameters (location, the range of treated trabecular meshwork, 
the number of shot, or total laser energy) and treatment success.125 126 129 135 136 137 138 142 
148 157 158   
Type of glaucoma medication 
Prostaglandin analogues  
Hirn et al.124 compared prostaglandin analogues (PGAs) naïve patients with PGAs users 
and found IOP reduction was significantly greater in the PGAs naïve group after the SLT 
treatment during the 1-year follow-up. A comparable conclusion was drawn from Bruen 
et al., stating that PGAs used at baseline was negatively associated with IOP-lowering 
effect after adjusting for baseline IOP.128 Compared to timolol/dorzolamide fixed 
combination users, PGAs users showed a less efficacy of SLT treatment in the study of  
Kara et al.159 Furthermore, Alvarado et al. suggested a positive  PGAs response predicted 
both treatment success and IOP reduction magnitude after SLT, and those using PGAs at 
baseline had a poor SLT treatment outcome.133 While those studies demonstrated a 
negative association between PGAs and SLT treatment effect, Scherer et al. found 
patients using PGAs before and during the perioperative period had a greater absolute or 
percentage IOP reduction than those without using PGAs.160 
Carbonic anhydrase inhibitors  
Woo et al.161 conducted a five-year retrospective study to explore the correlation between 
the IOP-lowering medications and SLT response. In total, 206 eyes from 206 patients 
with POAG, PDS, PXF, or OHT were included in the study. Among the 206 patients, 55 
completed the five-year follow-up. The result showed systemic or topical carbonic 
anhydrase inhibitors (CAIs) were significantly associated with a higher risk of failure 
during 60 months after a primary SLT (hazard ratio = 1.852; 95% CI, 1.175 to 2.919; p = 
0.008). By contrast, Lee et al. found a positive independent association between topical 
CAIs and SLT success at 1 month for POAG and normal tension glaucoma patients (OR 
= 18.63; 95% CI, 2.92 to 140.07; p = 0.002).158  
  
32 
A number of other studies did not find a predictive effect of the type of glaucoma 
medication regarding SLT or ALT efficacy.122 123 126 132 135 137 147 148 162 
Number of glaucoma medication 
Lee et al. found using three types of IOP-lowering medications at baseline was negatively 
associated with SLT success in either univariate (OR = 0.34; 95% CI, 0.11 to 0.94; p = 
0.037) or multivariate regression (OR = 0.02; 95% CI, 0.00 to 0.32; p = 0.0081) 
analysis.158 However, other studies did not find such a significant association.122 123 132   
2.4 Summary 
Previous RCTs comparing SLT and ALT agreed with each other and concluded that SLT 
was comparable to ALT regarding IOP-lowering effect in patients with primary or 
secondary OAG or patients with OHT when used in laser naïve eyes. Repeat SLT had an 
equivalent IOP reduction efficacy compared with primary SLT though this has mostly 
been studied in case series with methodological limitations. No study has reported about 
the comparison of the efficacy of SLT versus ALT in patients who have received primary 
SLT. Baseline IOP as the prognostic factor for SLT or ALT success has been confirmed by 
a large number of studies. Nevertheless, the previous studies drew divergent conclusions 
of the association between some other factors and the efficacy of laser trabeculoplasty. 
Therefore, it is reasonable to evaluate other potentially influential factors for the treatment 
success in this thesis.  
  
33 
Chapter 3 Methods 
 
In this chapter, five sections are included. Section 3.1 presents the basic information 
extracted from the protocol of the Repeat Laser Study to specify how the original data 
was created. Section 3.2 describes the data cleaning procedures. Methods of the primary 
outcome, secondary outcomes and subgroup analyses are reported in Section 3.3 along 
with sensitivity analyses. Section 3.4 illustrates the development and assessment of the 
prediction model for laser success. Section 3.5 is a summary.  
3.1 Basic information of the Repeat Laser Study 
Trial design 
The Repeat Laser Study is a multicenter, patient-masked, randomised, parallel-group, 
active-controlled, equivalence trial in seven academic hospitals from seven cities of 
Canada: Halifax, Toronto, London, Edmonton, Calgary, Hamilton, and Montreal.  
Participants 
Inclusion criteria: 
• Equal to or more than 18 years of age; 
• Primary open-angle glaucoma (POAG), pigmentary dispersion syndrome (PDS) 
pseudoexfoliation syndrome (PXF), or ocular hypertension (OHT); 
• Previous 360-degree SLT;  
• Intraocular pressure (IOP) greater than 16 mmHg on at least two different days 
within one month; 
• Both of the eyes had to have best-corrected visual acuity at least 20/200;  
• If the patients were treated in two eyes, the first treated eye (usually the eye with 
higher IOP) decided by the physician will be recruited in the study; 
• Willing to participate. 
Exclusion criteria: 
• Secondary open-angle glaucoma (other than PDG and PXF) or narrow-angle 
  
34 
glaucoma (defined as the anterior trabecular meshwork is not visible 360 degrees); 
• Previous non-laser glaucoma surgery; 
• Intraocular surgery is anticipated in the 12 months after laser treatment; 
• Corneal disease which can obscure acceptable visualization of the trabecular 
meshwork or can create an unreliable IOP measurements; 
• Topical or systematic steroids is used at present or systematic steroid is prospected 
to be used in the 6 months after laser treatment; 
• Previous ALT treatment; 
• Pregnant or breastfeeding females. 
Settings and locations 
Eligible patients were identified and recruited by glaucoma specialists in their practices, 
where the laser was performed.  
Randomisation and allocation 
The randomisation and allocation schedule was generated by the study coordinating 
centre in the Ivey Eye Institute at University of Western Ontario with the technical 
support from the Lawson Research Kidney Research Unit, LHSC, London Ontario. 
Randomisation was phone-based by the Lawson Research Kidney Research Unit. A 
randomised block of 4, 6, 8 at each centre was conducted. Participants were randomised 
with 1:1 allocation ratio to either SLT or ALT according to the allocation schedule created 
by the software (STATA, College Station Texas).  
After the enrolment of the patients by the local ophthalmologist, the site based study 
coordinator accessed the randomised allocation and informed the ophthalmologist. The 
participants and the technicians responsible for IOP, visual acuity, and central corneal 
thickness (CCT) tests were masked to the type of laser treatment. Treatment allocation 
was not blinded for the persons who were responsible for the data analysis. 
Procedures 
Basic information of participants, including demographics, glaucoma risk factors, medical 
history, and concomitant medications, were recorded at the baseline visit.  
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Before laser treatment in the study, baseline IOP was the average of at least three IOP 
measurements taken on two separate days within one month. When measuring IOP, 
Goldmann applanation tonometer was used. The mire and dial were read by different 
people. IOP at each measurement was taken two times if the difference was within 2 
mmHg. If the difference was ≥ 3 mmHg, the third measurement was taken, and the 
median of the three measurements was used for data analysis.  
Other baseline measurements included best-corrected visual acuity (BCVA) with Snellen 
chart, a slit-lamp assessment for the anterior segment, stereoscopic optic nerve exam, 
central corneal thickness (CCT) with ultrasound pachymetry, and gonioscopy with 
goniolens. Anterior chamber inflammation was recorded as cell scoring: 0 = 0 cell, +0.5 = 
1 to 5 cells (trace), +1 = 6 to 15 cells, +2 = 16 to 25 cells, +3 = 26 to 50 cells, +4 ≥ 50 
cells; and flare scoring: 0 = none, 1 = faint, +2 = moderate, +3 = marked, +4 = intense. 
The gonioscopy grading used the Modified Shaffer grading based on the most visible 
angle structure: 0 = closed, grade 1 = Schwalbe’s line visible, grade 2 = trabecular 
meshwork, 3= scleral spur, 4 = ciliary body band. The pigment of trabecular meshwork 
was graded as: 0 = none, 1 = light, 2 = medium, 3 = dark brown, 4 = almost black. 
Peripheral anterior synechiae were recoded as present or absent.  
Consenting and baseline eye examination was preferably on the same day or at most 
within one week before the laser treatment. Before the laser therapy, IOP was measured. 
The recruited patient received either SLT or ALT treatment. Before and after the laser 
treatment, 0.15% brimonidine was used in the treatment eye. The inferior 180-degree of 
trabecular meshwork was treated. Selecta 7000 was used for SLT. The laser was 
standardised with 400-𝜇m spot size and 3-ns duration, and it was centred on the 
trabecular meshwork with 50 non-overlapping applications. The starting energy was 0.7 
mJ, and then was adjusted until the bubble formation appeared, and finally was decreased 
by 0.1mJ for the rest of treatment. The laser of ALT was set with 50-𝜇m spot size, 0.1-
second duration, and a power ranging from 400 to 800 mW. The ALT was performed 
through an antireflective coated Goldman lens with 50 applications. The energy was set to 
generate blanching or occasional bubble formation in the anterior trabecular meshwork.  
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After the laser treatment, participants completed 6 follow-up visits at the following time 
points: 1 hour ± 30 min, 1 week ± 2 days, 1 month ± 7 days, 3 months ± 10 days, 6 
months ± 2 weeks, and 12 months ± 3 weeks.  
Outcomes 
The primary outcome of the Repeat Laser Study was IOP change from baseline to the 12- 
month follow-up compared between the two lasers. 
The pre-specified secondary outcomes included:  
• IOP change from baseline to every post-laser visit except for the post-laser 1-hour 
measurement; 
• Success of laser treatment. Success was defined as a IOP reduction of more than 2 
mmHg from baseline; 
• Snellen visual acuity, which was converted to LogMAR unit, at every post-laser 
visit; 
• Proportion of absence of anterior chamber inflammation at every post-laser visit; 
• Proportion of trabecular meshwork pigmentation graded 2 to 4 at 12-month follow-
up visit; 
• Number of glaucoma medications needed per patient at 12-month follow-up visit; 
• Glaucoma surgery during 12-month follow-up; 
• IOP spike, which was defined as an elevation of IOP > 5 mmHg at 1 hour.  
Sample size 
The sample size calculation was based on the IOP change from baseline to the 12-month 
follow-up. Equivalence was claimed if the 95% confidence interval of the mean 
difference between two treatment groups lies within -3 mmHg and +3 mmHg. The margin 
was pre-decided by the study group based on the clinically meaningful difference along 
with previous statistical outcomes and feasibility. It was not usual that the glaucoma 
treatment strategy will change with less than 3 mmHg difference of IOP. Also, it was 
recommended by the FDA that the margin should be less than the effect of active control 
treatment.163 Previous studies showed ALT reduced baseline IOP by approximately 3.2 to 
9.6 mmHg at 12 months.58 59 60 61 62 63 Therefore, choosing 3 mmHg as the equivalence 
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margin was satisfied with the FDA guideline. Assuming a 90% chance with Type I error 
rate of 0.05 that a 95% confidence interval can exclude a difference of more than 3 
mmHg, which was determined as the clinically meaningful difference, the trial would 
need to recruit 117 eyes totally. Enrolling approximately 137 eyes would allow for 10% 
protocol violation and loss to follow-up. 
Data collection  
Data were recorded on standardised paper forms by the research coordinators, and then 
the data was inputted to the web-based data system.  
3.2 Data cleaning 
Recheck data entry accuracy and correct errors 
The records in the paper forms and the study website were compared for 14 (10%) of the 
137 randomised participants consecutively treated in the Ivey Eye Institute, London, ON. 
Approximately 314 inputs for each patient, namely 4396 inputs in total, were compared.  
There were 11 of 4396 (0.3%) missing values and 32 of 4396 (0.7 %) errors. On average, 
approximately 3 missing values or errors were found per participant. The most common 
errors were seen in history documentation (10 missing values, 5 errors in previous IOP 
records, and 5 other errors) and visual acuity test (12 errors). IOP measurement values 
were wrong in 3 inputs. Other errors were identified in laser parameters, anterior chamber 
inflammation, and trabecular meshwork pigmentation data. The details of errors and 
missing values are shown in Appendices 1A and 1B. All those errors and missing values 
were corrected before the data analyses. 
Problematic data in digital data sets 
Detection and correction of problematic data in the digital data sets included: searching 
for missing data and determining if the missing can be avoided, detecting outliers, 
checking inclusion and exclusion criteria, checking logic and consistency of variables 
recorded in different tables, recording suspected data errors, consulting study coordinators 
or participants for problematic data if possible, and editing suspected or confirmed error 
data in the following ways: deletion, correction, no change, or imputation.  
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Among the 111 variables used for future data analyses of the 137 patients in the digital 
tables, 31 errors and 8 missing values were detected and modified if possible (Appendices 
2A to 2D). Since the missing rate of medication treatment time was up to 38% (Appendix 
3), it suggested that this kind of information was not available. Therefore, we addressed 
the problem with imputation. The missing start month and start year of medications were 
imputed with “January” and “2000” respectively. When the stop year of medication was 
recorded without stop month, it was imputed with “January”. In addition, after a logic and 
consistency check, 17 errors were corrected (Appendix 2E and Appendix 3). Also, 
violation of inclusion and exclusion criteria were found in some patients, and those 
patients were kept in the complete case analyses (Appendix 3). 
3.3 Outcome analyses 
Primary and secondary outcome analyses 
The primary outcome was analysed for the complete cases (modified intention-to-
treat),164 165 who did not have missing data in the primary and secondary outcomes or the 
variables used in the prediction model. To assess the equivalence between SLT and ALT 
in IOP change at 12 months, the mean difference between the two laser treatments and the 
95% CI was derived by an independent two-sample t-test. If the 95% CI of the mean 
difference between the two laser groups falls within the proposed margin of equivalence 
(-3 mmHg to +3 mmHg), the two types of trabeculoplasty can be claimed equivalent. 
Before the independent two-sample t-test was conducted, normality of the samples of the 
two groups was determined by visualizing the histogram. Homogeneity of variance 
between the two treatment groups was analysed using F test.  
All the secondary outcomes were also analysed based on the complete cases and tested 
for the superiority of SLT versus ALT. An independent two-sample t-test was used for the 
continuous outcomes. For the binary outcomes, results were presented as risk difference 
(RD) and relative risk (RR) with 95% CI.  A two-sided p value < 0.05 was considered 
significant. 
Subgroup analyses  
The primary outcome was analysed in the planned subgroups, which were set up after the 
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assessment of the baseline characteristics: 
• POAG patients 
• Baseline IOP < 22 mmHg vs ≥ 22 mmHg 
• Patients aged < 66 years of age vs patients ≥ 66 years of age 
• Females vs males 
• Patients with two or less glaucoma risk factors vs more than two glaucoma risk 
factors; 
• CCT < 556 𝜇𝑚 vs CCT ≥ 556 𝜇𝑚 
• With vs without glaucoma medications at baseline 
• PGAs users vs non-PGAs users at baseline (PGAs users included those who used 
PGAs monotherapy or PGAs fixed combination) 
• CAIs users vs non-CAIs users at baseline (CAIs users included those who used 
CAIs monotherapy or CAIs fixed combination) 
• The most recent SLT treatment ≥ 3 years vs <3 years before the study  
Sensitivity analyses 
The primary outcome analysis was repeated for the per-protocol population. Patients who 
had increased the number of medication, received a glaucoma surgery, or received 
another glaucoma laser treatment during the 12-month follow-up were considered 
protocol violation. A sensitivity test for the primary endpoint was also conducted with 
extreme case analysis (the best & worst case assessment),165 in which the missing IOP at 
12 months were imputed with the minimum IOP among all the participants in the SLT 
group and the maximum IOP among those in the ALT group, and reverse. 
3.4 Creating a regression model to explore the predictors 
for laser treatment success 
Source of data 
The data from the complete cases were used in the prediction model development. 
Outcome 
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The outcome in the prediction model was laser treatment success, which was defined as 
IOP change > 2 mmHg from baseline to 12-month follow-up. The detail of IOP test is 
described in Section 3.1.  
Candidate predictors 
Candidate predictors were selected based on previous studies, which have found a 
significant association between the predictors and efficacy of laser trabeculoplasty 
(Section 2.3 in Chapter 2).  
Candidate predictors included age (years), baseline IOP (mmHg), CCT (𝜇m), grade of 
trabecular meshwork pigmentation (0-4), number of concurrent glaucoma medication (0-
3), prostaglandin analogues (PGAs) users, and carbonic anhydrase inhibitors (CAIs) 
users. All the variables were measured and recorded before the laser treatment. The 
measurements were blinded, while the analyses were not blinded for the treatment 
allocation. In addition, all the variables were coded as quantitive variables in the 
regression model.  
No missing values were left in the candidate predictors. Regarding the imputation for the 
time of medication treatment, details are provided in Section 3.2.  
Model development  
After the univariate analyses to evaluate the correlation of each candidate predictor with 
the outcome, a logistic regression model was created to explore the association of the 
potential predictors with the success of laser treatment. Predictors were selected 
automatically using backward stepwise method with a p value greater than 0.15 for 
removal. Interaction terms were not examined in such a relatively small sample size.166 
Model performance  
Model performance was analysed with discrimination and calibration. Discrimination 
ability of the model was assessed by Receiver Operating Characteristic (ROC) curve.167 
Hosmer-Lemeshow (H-L) goodness-of-fit test was used to test the calibration property.168 
A significant result of H-L test suggests a poor prediction model. A calibration graph was 
developed to visually evaluate the agreement between predictive and observed outcomes.  
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Internal validation 
Bootstrapping was used to assess internal validation and to correct overly optimistic 
measures of model fit.169 The procedure repeated 1000 times to create an estimation of the 
population parameter.  
3.5 Summary 
The data used in this thesis was obtained from a multicenter, patient-masked, randomised, 
parallel-group, active-controlled, equivalence trial comparing ALT and SLT in lowering 
IOP effect. The primary outcome was IOP change from baseline to 12-month visit. The 
errors or missing values of the primary or secondary outcomes were sparse in the data sets. 
The independent two-sample t-tests were performed to evaluate the equivalence of the 
primary outcome and the superiority of the secondary continuous outcomes between the 
two laser treatment groups. For the binary outcomes, both RD and RR were analysed. To 
explore the predictors for treatment success, both univariate analysis and Logistic 
regression analysis were conducted. Backward stepwise selection of independent 
variables was applied. Model performance was evaluated with ROC curve, Hosmer-
Lemeshow (H-L) goodness-of-fit test, and calibration graph. Bootstrap resampling 
method was also used to assess the internal validity of the final model.  
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Chapter 4 Results 
 
There are three sections in this chapter. Section 4.1 includes the study flow chart and 
describes baseline characteristics of study participants. Analyses evaluating the 
equivalence of treatment groups for the primary and secondary study outcomes are then 
summarised in Section 4.2 along with subgroup analyses and sensitivity analyses of the 
primary outcomes. Finally, results from a 12-month predictive model of successful IOP 
reduction are presented in Section 4.3.  
4.1 Descriptive statistics 
Data collection procedures 
The first patient was recruited and received laser treatment in the study on February 14, 
2013. The last patient was recruited and received laser treatment on October 24, 2016. 
The duration of recruitment was around 3 years and 8 months. 
Of the 167 patients who had approached to participate in the study, 28 were ineligible for 
several reasons. Randomisation was performed for 139 patients with 69 assigned to the 
selective laser trabeculoplasty (SLT) group and 70 to the argon laser trabeculoplasty 
(ALT) group. Before receiving the allocation intervention, one patient in each group was 
identified not eligible (Figure 2). The baseline characteristics of these two patients were 
not recorded in the study database. 
By June 20, 2017, when data analysis began, 128 patients had completed the 12months 
after their laser treatment date. Among the 128 patients, 7 patients were withdrawn from 
the study for reasons, 1 patient missed one of the follow-up visits, and 5 patients had one 
missing value for data analysis. Therefore, 115 patients were available for the complete 
case analyses (Figure 2).  
Baseline characteristics of participants 
Among the 115 patients, over 80% were Caucasian in both groups. Around 70% were 
diagnosed as primary open-angle glaucoma (POAG) in both groups. The mean baseline 
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intraocular pressure (IOP) was comparable between the two laser groups with 21.67 
mmHg in the SLT group and 21.77 mmHg in the ALT group. Best-corrected visual acuity 
(BCVA), modified Schaffer grade, trabecular meshwork pigmentation, peripheral anterior 
synechiae, cup to disc ratio, and the number of medication used at baseline were also well 
balanced between the two groups. Details of the baseline characteristics are shown in 
Table 1A and Table 1B. 
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Figure 2: Flow chart of the Repeat Laser Study 
 
ALT: argon laser trabeculoplasty; BCVA: best-corrected visual acuity; IOP: intraocular pressure; 
SLT: selective laser trabeculoplasty; TMP: trabecular meshwork pigmentation.   
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Table 1A: Baseline characteristics of patients in complete case analyses 
 SLT (n= 57) ALT (n= 58) 
Centre   
 Western University 15 (26%) 14 (24%) 
University of Toronto 9 (16%) 11 (19%) 
University of Calgary 15 (26%) 12 (21%) 
University of Alberta 2 (4%) 2 (3%) 
Dalhousie University 13 (23%) 14 (24%) 
McMaster University 3 (5%) 5 (9%) 
Study eye was right eye 23 (40%) 37 (64%) 
Male 29 (51%) 34 (59%) 
Age (years)    
 Mean ± SD 64.71 ± 10.85 66.50 ± 9.56 
 Range 35 to 93 42 to 89 
Ethnicity   
 Caucasian 48 (84%) 50 (86%) 
 African 2 (4%) 3 (5%) 
 Others 7 (12%) 5 (9%) 
BCVA (LogMAR)    
 Mean ± SD 0.10 ± 0.12 0.13 ± 0.23 
 range -0.12 to 0.48 -0.10 to 1.00 
IOP (mmHg)   
 Mean ± SD 21.67 ± 3.15 21.77 ± 3.35 
 range 16.50 to 29.50 15.50 to 32.50 
CCT (μm)   
 Mean ± SD 552.14 ± 37.44 562.59 ± 37.83 
 range 452.00 to 618.00 484.00 to 682.00 
Modified Schaffer (0-4)    
 2 2 (4%) 2 (3%) 
 3 30 (53%) 31 (53%) 
 4 25 (44%) 25 (43%) 
TMP (0-4)    
 0 5 (9%) 6 (10%) 
 1 27 (47%) 30 (52%) 
 2 19 (33%) 19 (33%) 
 3 5 (9%) 2 (3%) 
 4 1 (2%) 1 (2%) 
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Table 1B: Baseline characteristics of patients in complete case analyses 
 SLT (n= 57) ALT (n= 58) 
PAS (Present) 2 (4%) 1 (2%) 
Cup to disc ratio    
 Mean ± SD 0.64 ± 0.19 0.66 ± 0.17 
 Range 0.20 to 0.90 0.20 to 0.90 
Risk factors    
 Family History of POAG 21 (37%) 21 (36%) 
 Age (above 60) 41 (72%) 48 (83%) 
 Myopia 13 (23%) 17 (29%) 
 Elevated IOP (above 21 mmHg) 38 (67%) 41 (71%) 
 Ethnic Background  
(labeled as “yes” if not Caucasian) 
9 (16%) 8 (14%) 
 Concomitant medical conditions 
(hypertension, diabetes, 
hypothyroidism) 
15 (26%) 21 (36%) 
 Others 4 (7%) 0 (0%) 
Number of glaucoma medication used at 
baseline  
  
 0 26 (46%) 28 (48%) 
 1 16 (28%) 11 (19%) 
 2 13 (23%) 14 (24%) 
 3 2 (4%) 5 (9%) 
Diagnosis   
 POAG 41 (72%) 40 (69%) 
 PDS 3 (5%) 3 (5%) 
 PXF 7 (12%) 11 (19%) 
 OHT 5 (9%) 4 (7%) 
 PXF & OHT 1 (2%) 0 (0%) 
ALT: argon laser trabeculoplasty; ACI: anterior chamber inflammation; BCVA: best-corrected 
visual acuity; CCT: central corneal thickness; IOP: intraocular pressure; OD: oculus dexter (right 
eye); OHT (OHT was defined as IOP > 21 mmHg, open drainage angles observed on gonioscopy 
without glaucomatous optic disc damage, detectable nerve fibre layer defect, or visual field loss.): 
ocular hypertension; OS: oculus sinister (left eye); PAS: peripheral anterior synechiae; PDS: 
pigmentary dispersion syndrome; POAG: primary open-angle glaucoma; PXF: pseudoexfoliation 
syndrome; SD: standard deviation; SLT: selective laser trabeculoplasty; TMP: trabecular 
meshwork pigmentation. 
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The mean ± SD actual spot size was 403.51±18.56 𝜇𝑚 (range: 400 to 500 𝜇𝑚) for SLT 
and 52.17±4.36 𝜇𝑚 (range: 50 to 66 𝜇𝑚) for ALT. The mean duration was 3 ns for SLT 
and 0.1 seconds for ALT as planned. The actual mean ± SD number of laser application 
was 50.33±1.53 (range: 46 to 58) in the SLT group and 51.60±3.41 (range: 50 to 70) in 
the ALT group. The mean ± SD total energy was 46.82±9.64 mJ (range: 25 to 70 mJ) for 
SLT treatment and 3286.77±513.54 mW (range: 2000 to 4000 mW) for ALT treatment. It 
should be noted that because the lasers are fundamentally different, we would not expect 
the laser parameters to be the same in each group. 
The actual timing of observations after the laser treatment had a larger deviation in the 
ALT group than the SLT group at post-laser 1 hour, 1 week, 6 months, and 12 months 
(Table 2. and Figure 3).  
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Table 2: Follow-up schedule and actual follow-up time 
Schedule 1 hour±30 minutes 1 week±2 days 1 month±7 days 3 months±10 days 6 months±2 weeks 12 months ±3 weeks 
SLT 
 
1 hour±13 minutes 
(30 to 104 minutes) 
1 week±1 day 
(5 to 12 days) 
1 month±5 days 
(2 to 7 weeks) 
3 months±9 days 
(9 to 17 weeks) 
6 months±2 weeks 
(5 to 9 months) 
12 months±2 weeks 
(11 to 14 months) 
ALT 
 
1 hour±32 minutes 
(30 to 265 minutes) 
1 week±4 days 
(4 to 38 days) 
1 month±5 days 
(3 to 6 weeks) 
3 months±9 days 
(10 to 17 weeks) 
6 months±3 weeks 
(3 to 9 months) 
12 months±3 weeks 
(11 to 16 months) 
ALT: argon laser trabeculoplasty; SLT: selective laser trabeculoplasty. Note: data are presented as mean±standard deviation (range). 
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Figure 3: Timing of observations in the Repeat Laser Study 
 
Note: Each row represents a randomised patient in the study; the dots correspond to the actual 
date of the follow-up visits after the laser treatment. 
4.2 Analyses of the outcomes 
Primary outcome (IOP change from baseline to the 12-month follow-up) 
Among the 115 patients with complete data, the mean change of IOP from baseline to 12 
months was 3.35 mmHg (95% CI, 2.03 to 4.66 mmHg) in the SLT group and 3.35 mmHg 
(95% CI, 2.03 to 4.69 mmHg) in the ALT group, with a difference of -0.01 mmHg (95% 
CI, -1.86 to 1.84 mmHg). The 95% CI of the difference of IOP change was within the 
equivalence range of the -3 to +3 mmHg boundary. (Table 3 and Figure 4) 
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Table 3: IOP change (mmHg) from baseline to the 12-month visit 
 
SLT 
N, mean(SD) 
ALT 
N, mean(SD) 
Difference of the IOP 
change (95% CI) 
Complete case 
analysis 
57, 3.35 (4.96) 58, 3.36 (5.06) -0.01 (-1.86 to 1.84) 
Per-protocol 
analysis 
46, 3.43 (3.87) 38, 2.87 (3.15) 0.56 (-0.99 to 2.12) 
ALT: argon laser trabeculoplasty; CI: confidence interval; IOP: intraocular pressure; SD: standard 
deviation; SLT: selective laser trabeculoplasty. 
Figure 4: Difference of mean IOP change (mmHg) from baseline to the 12-month 
visit between the ALT and SLT group 
 
 
ALT: argon laser trabeculoplasty; CI: confidence interval; IOP: intraocular pressure; SLT: 
selective laser trabeculoplasty. Two dash lines represent the clinical equivalence range. 
Secondary outcomes 
IOP change from baseline to different post-laser visits 
The IOP reductions at one week and one month after the laser treatment were greater in 
the SLT group compared to the ALT group. The 95% CIs of the IOP change difference 
between the two treatment groups at post-laser treatment 3 months and 6 months were 
within the equivalent boundary (Table 4, Figure 5).  
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Table 4: IOP change (mmHg) from baseline to different time points 
 
 
SLT (n = 57) 
mean (SD) 
ALT (n= 58) 
mean (SD) 
Difference (95% CI) P value 
1 week 3.23 (4.53) 1.42 (3.56) 1.82 (0.31 to 3.32) 0.02* 
1 month 4.69 (3.84) 2.81 (3.66) 1.88 (0.50 to 3.27) 0.01* 
3 months 4.34 (2.97) 3.43 (4.81) 0.91 (-0.57 to 2.40) 0.22 
6 months 3.28 (3.73) 3.50 (4.08) -0.22 (-1.66 to 1.22) 0.76 
ALT: argon laser trabeculoplasty; BCVA: best corrective visual acuity; CI: confidence interval; 
IOP: intraocular pressure; SD: standard deviation; SLT: selective laser trabeculoplasty. * indicates 
a p value < 0.05. Data were analysed based on complete cases. 
Figure 5: IOP at different time points 
 
ALT: argon laser trabeculoplasty (n= 58); CI: confidence interval.; IOP: intraocular pressure; 
SLT: selective laser trabeculoplasty (n = 57). Data were analysed based on complete cases. 
Laser success rate at different post-laser visits 
The success of laser treatment was defined as IOP reduction greater than 2 mmHg from 
baseline. The success rate was between 61% to 81% in the SLT group and 43% to 64% in 
the ALT group during the 12-month follow-up. At the 1-week, 1-month, and 3-month 
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post-laser visit, the success rate was significantly greater in the SLT group than the ALT 
group (Table 5).  
Table 5: Number of patients with treatment success (an IOP reduction more than 2 
mmHg from baseline) at different time points 
 
SLT 
(n=57) 
ALT 
(n=58) 
RD (95% CI, p) RR (95% CI, p) 
1 week 37 (65%) 25 (43%) 0.22 (0.04 to 0.40, 0.02)* 1.51 (1.06 to 2.14, 0.02)* 
1 month 44 (77%) 34 (59%) 0.19 (0.02 to 0.35, 0.03)* 1.32 (1.02 to 1.71, 0.04)* 
3 months 46 (81%) 36 (62%) 0.19 (0.02 to 0.35, 0.03)* 1.30 (1.02 to 1.65, 0.03)* 
6 months 35 (61%) 37 (64%) -0.02 (-0.20 to 0.15, 0.79) 0.96 (0.72 to 1.28, 0.79) 
12 months 37 (65%) 36 (62%) 0.03 (-0.15 to 0.20, 0.75) 1.05 (0.79 to 1.38, 0.75) 
ALT: argon laser trabeculoplasty; CI: confidence interval; IOP: intraocular pressure; RD: risk 
difference; RR: relative risk; SLT: selective laser trabeculoplasty. * indicates a p value < 0.05. 
Data were analysed based on complete cases. 
Best-corrected visual acuity (BCVA) at each visit 
The mean BCVA was comparable between the two laser treatment groups at all the 
follow-up visits (Table 6).  
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Table 6: BCVA (LogMAR) at different time points 
 
SLT (n =57) 
mean (SD)  
ALT (n=58) 
mean (SD) 
 Difference (95% CI)       P value 
Baseline 0.10 (0.12) 0.13 (0.23) -- -- 
1 hour 0.13 (0.14) 0.15 (0.26) -0.02 (-0.10 to 0.05) 0.57 
1 week 0.09 (0.12) 0.11 (0.22) -0.03 (-0.09 to 0.04) 0.46 
1 month 0.09 (0.12) 0.13 (0.22) -0.04 (-0.11 to 0.02) 0.20 
3 months 0.09 (0.16) 0.11 (0.22) -0.02 (-0.09 to 0.05) 0.55 
6 months 0.09 (0.14) 0.13 (0.24) -0.03 (-0.11 to 0.04) 0.39 
12 months 0.07 (0.13) 0.13 (0.25) -0.06 (-0.14 to 0.01) 0.09 
ALT: argon laser trabeculoplasty; BCVA: best-corrected visual acuity; CI: confidence interval; 
SD: standard deviation; SLT: selective laser trabeculoplasty. Data were analysed based on 
complete cases. 
Anterior chamber inflammation at each visit  
Eleven (19%) patients in the SLT group and 12 (21%) patients in the ALT group used the 
topical steroid to control post-laser anterior chamber inflammation. About 70% patients 
had anterior chamber inflammation at 1hour after the laser treatments. The mean ± SD 
anterior chamber cells grade at post-laser one hour was 0.51 ± 0.48 (range 0 to 2) in the 
SLT group and 0.32 ± 0.28 (range 0 to 1) in the ALT group. The difference was 
significant with p = 0.01 (mean difference, 0.19; 95% CI, 0.05 to 0.33). The percentage of 
patients with cleared ocular inflammation (cell grade 0 and flare grade 0) was 
significantly lower in the SLT group than the ALT group at post-laser 1 week. The 
proportion was comparable between the two groups at the rest of the visit time points 
(Table 7).  
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Table 7: Number of patients without anterior chamber inflammation at different 
time points 
 
SLT 
(n=57) 
ALT 
(n=58) 
RD (95% CI, p) RR (95% CI, p) 
Baseline 56 (98%) 58 (100%) -- -- 
1 hour 15 (26%) 21 (36%) -0.10 (-0.27 to 0.07, 0.25) 0.73 (0.42 to 1.27, 0.26) 
1 week 43 (75%) 54 (93%) -0.18 (-0.31 to -0.05, 0.01)* 0.81 (0.69 to 0.96, 0.01)* 
1 month 53 (93%) 56 (97%) -0.04 (-0.12 to 0.05, 0.39) 0.96 (0.88 to 1.05, 0.39) 
3 months 55 (96%) 58 (100%) -0.04 (-0.08 to 0.01, 0.15) 0.96 (0.92 to 1.01, 0.16) 
6 months 57 (100%) 57 (98%) 0.02 (-0.02 to 0.05, 0.32) 1.02 (0.98 to 1.05, 0.32) 
12 months 55 (96%) 57 (98%) -0.02 (-0.08 to 0.04, 0.55) 0.98 (0.92 to 1.04, 0.55) 
ALT: argon laser trabeculoplasty; CI: confidence interval; RD: risk difference; RR: relative risk; 
SLT: selective laser trabeculoplasty. * indicates a p value < 0.05. Data were analysed based on 
complete cases. 
Trabecular meshwork pigmentation at the 12-month follow-up visit 
The proportion of trabecular meshwork pigmentation greater than Grade 1 was 40% 
versus 38% at the 12-month follow-up in the SLT group versus the ALT group. The risk 
difference (RD) and relative risk (RR) were not significant between the two laser 
treatment groups at the 12-month visit (Table 8).  
Table 8: Number of trabecular meshwork pigmentation greater than Grade 1 at 
baseline and at 12 months 
 
SLT 
(n=57) 
ALT 
(n=58) 
RD (95% CI, p) RR (95% CI, p) 
Baseline 25 (44%) 22 (38%) -- -- 
12 months 23 (40%) 22 (38%) 0.02 (-0.15 to 0.20, 0.79) 1.06 (0.67 to 1.68, 0.79) 
ALT: argon laser trabeculoplasty; CI: confidence interval; RD: risk difference; RR: relative risk; 
SLT: selective laser trabeculoplasty. Data were analysed based on complete cases. 
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Number of glaucoma medications needed per patient at 12-month follow-up visit 
The number of glaucoma medications used at 12 months was comparable between the 
two laser treatment groups (Table 9).  
Table 9: Number of medication used per person at baseline and at 12 months 
 
SLT (n = 57) 
mean(SD)  
ALT (n= 58) 
mean(SD) 
Difference  
 (95% CI) 
P value 
Baseline 0.84 (0.90) 0.93 (1.04) -- -- 
12 months 1.07 (0.96) 1.24 (1.06) -0.17 (-0.55 to 0.20) 0.37 
ALT: argon laser trabeculoplasty; CI: confidence interval; SLT: selective laser trabeculoplasty. 
Data were analysed based on complete cases. 
Glaucoma surgery during 12-month follow-up 
One patient (2%) in the SLT group and 4 (7%) in the ALT group progressed to surgery 
(laser trabeculoplasty, iStent, trabeculectomy, or more than one of those kinds of surgery) 
during the 12-month follow-up. The RD was -0.05 (95% CI -0.13 to 0.02; p = 0.18), and 
RR was 0.25 (95% CI, 0.03 to 2.23; p = 0.22) between the SLT and ALT group.  
IOP spike 
IOP spike, which was defined as an elevation of IOP > 5 mmHg from baseline, was 
found in 0/57 (0%) and 0/58 (0%) patient in the SLT and ALT groups respectively at the 
post-laser 1-hour test.  
Subgroup analyses 
The subgroup analyses based on diagnosis of POAG, baseline IOP, age, gender, 
glaucoma risk factors, central corneal thickness (CCT), number of glaucoma medicine 
used at baseline, prostaglandins analogues (PGAs) users, carbonic anhydrase inhibitors 
(CAIs) users, and time of previous SLT showed an equivalent IOP reduction effect or a 
non-significant IOP change difference at 12 months between the SLT and ALT group 
(Table 10 Figure 6). 
  
  
56 
Table 10: IOP change (mmHg) from baseline to the 12-month visit in subgroups 
Subgroup 
SLT  
N, mean(SD) 
ALT  
N, mean(SD) 
Mean 
Difference (95%CI) 
POAG 41, 2.67 (3.64) 40, 3.22 (4.85) -0.55 (-2.45 to 1.35) 
Baseline IOP < 22 mmHg 33, 2.67 (2.88) 32, 2.05 (3.72) 0.61 (-1.03 to 2.26) 
Baseline IOP ≥ 22 mmHg 24, 4.28 (6.84) 26, 4.96 (6.02) -0.68 (-4.34 to 2.98) 
Age < 66 years 30, 3.28 (3.25) 27, 2.25 (4.61) 1.02 (-1.08 to 3.13) 
Age ≥ 66 years 27, 3.43 (6.42) 31, 4.32 (5.31) -0.89 (-3.98 to 2.19) 
Female 28, 2.71 (5.76) 24, 2.78 (4.68) -0.07 (-3.03 to 2.88) 
Male 29, 3.97 (4.04) 34, 3.76 (5.34) 0.20 (-2.22 to 2.62) 
Glaucoma risk factors ≤ 2 32, 3.92 (5.54) 25, 4.06 (5.78) -0.14 (-3.16 to 2.88) 
Glaucoma risk factors > 2 25, 2.61 (4.09) 33, 2.82 (4.45) -0.21 (-2.50 to 2.07) 
CCT < 556 𝜇𝑚 30, 4.05 (4.67) 27, 3.64 (5.74) 0.41 (-2.35 to 3.18) 
CCT ≥ 556 𝜇𝑚 27, 2.57 (5.23) 31, 3.11 (4.47) -0.55 (-3.10 to 2.01) 
No glaucoma medicine 
used at baseline 
26, 3.02 (5.34) 28, 4.38 (2.89) -1.35 (-3.67 to 0.97) 
At least one glaucoma 
medicine used at baseline 
31, 3.62 (4.69) 30, 2.41 (6.37) 1.21 (-1.65 to 4.07) 
Using PGAs at baseline 26, 2.59 (3.55) 25, 2.63 (6.80) -0.04 (-3.07 to 3.00)  
Not using PGAs at 
baseline 
31, 3.98 (5.87) 33, 3.91 (3.19) 0.07 (-2.27 to 2.42) 
Using CAIs at baseline 14, 1.56 (3.56) 19, 3.14 (7.71) -1.58 (-6.12 to 2.95) 
Not using CAIs at 
baseline 
43, 3.93 (5.24) 39, 3.46 (3.19) 0.47 (-1.46 to 2.40) 
Previous SLT < 3 years 31, 3.43 (5.27) 28, 4.28 (4.04) -0.85 (-3.32 to 1.62) 
Previous SLT ≥ 3 years  26, 3.25 (4.66) 30, 2.50 (5.79) 0.76 (-2.09 to 3.60) 
ALT: argon laser trabeculoplasty; CAIs: Carbonic anhydrase inhibitors; CCT: central corneal 
thickness; CI: confidence interval; IOP: intraocular pressure; PGAs: prostaglandin analogues; 
POAG: primary open-angle glaucoma; SLT: selective laser trabeculoplasty. Data were analysed 
based on complete cases.  
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Figure 6: Difference of mean IOP change from baseline to the 12-month visit 
between SLT and ALT in subgroups 
 
ALT: argon laser trabeculoplasty; CAIs: Carbonic anhydrase inhibitors; CCT: central corneal 
thickness; CI: confidence interval; IOP: intraocular pressure; PGAs: prostaglandin analogues; 
POAG: primary open-angle glaucoma; SLT: selective laser trabeculoplasty. Data were analysed 
based on complete cases. Two dash lines represent the clinical equivalence range. 
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Sensitivity analyses for the primary outcome 
• Per-protocol analysis 
Among the 115 patients with complete data, 31 patients were considered protocol 
deviations (4 underwent surgery or laser trabeculoplasty during the 12-month follow-up; 
26 added at least one additional glaucoma medication during 12-month follow-up; 1 had 
both of the above reasons). Therefore, 84 patients remained in the per-protocol analysis. 
Among the 84 protocol-adhering patients, the mean IOP reduction was greater in the SLT 
group with a difference of 0.56 mmHg (95% CI, -0.99 to 2.12 mmHg; p = 0.47) 
compared with the ALT group. The 95% CI of the difference of IOP change was within 
the equivalence range of the -3 to +3 mmHg boundary (Table 3, Figure 4). 
• Extreme case analyses  
For the 128 patients, who were at the date more than 12 months after the laser treatment 
by June 2017, two extreme case analyses were conducted. Among those patients, 121 
patients had the 12-month visit, and the 12-month IOP ranged between 8.5 to 38 mmHg. 
In the rest of 7 patients who did not have the 12-month visit, 4 were in the SLT group, 
and 3 were in the ALT group. If the IOP were imputed with 8.5 mmHg for the 4 patients 
in the SLT group and with 38 mmHg for the 3 patients in the ALT group, the difference 
of mean IOP change between the two groups was -1.34 mmHg (95% CI, -3.5 to 0.82; p = 
0.22). In reverse, when the IOP was imputed with 38 mmHg for the SLT patients and 8.5 
mmHg for the ALT patients, the difference was 1.89 mmHg (95% CI -0.23 to 4.02; p = 
0.08). Both the extreme case analyses did not show a significant difference of IOP change 
between the two treatment groups. 
Diagnostic test for the primary outcome before the independent two-sample t-test for 
the complete case analysis 
The histograms of the IOP change from baseline to 12 months for the two treatment 
groups are shown in Figure 7, which suggests a proximally normal distribution of the two 
samples. The test for homogeneity of the standard deviation of the IOP change between 
the two groups was not significant with p=0.88.  
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Figure 7: Histograms of IOP change from baseline to the 12-month visit in the ALT 
and SLT group based on complete cases 
 
4.3 Prediction model 
Model development 
In the 115 patients included in complete case analyses, 73 (63%) had a successful IOP 
reduction outcome at the 12-month follow-up (Table 11). The baseline characteristics are 
presented in Table 1A, 1B, and Table 11.  
In the model development process, 7 potential variables were evaluated. No missing data 
in the predictors and the outcome was encountered. The unadjusted analyses showed the 
IOP at baseline had a significant positive association with treatment success at 12 months 
(odds ratio 1.17; 95% CI, 1.02 to 1.34; p = 0.02). Using the p = 0.15 as the cut-off point 
in the backward variable selection, baseline IOP and number of glaucoma medications 
used at baseline were kept in the final model. The odds ratio (OR) in the final model and 
the model optimized after bootstrap method are shown in Table 11.  
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The optimized final model was expressed as 
log (
𝑃𝑠𝑢𝑐𝑐𝑒𝑠𝑠
1−𝑃𝑠𝑢𝑐𝑐𝑒𝑠𝑠
) = -2.74 + 0.17 baseline IOP - 0.46 number of glaucoma medications 
where 𝑃𝑠𝑢𝑐𝑐𝑒𝑠𝑠 represented the probability of treatment success at 12 months. Note also 
that baseline IOP (mmHg) and number of glaucoma medications were modeled as 
quantitive predictors.  
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Table 11: Unadjusted and adjusted association between each potential baseline predictor and outcome 
 
Success             
(n = 73) 
No success  
(n= 42) 
Univariate OR  
(95% CI, p) 
Multivariable OR after 
backward selection  
(95% CI, p) 
Multivariable OR after 
bootstrap  
(95% CI, p) 
Age, year 66.10 (10.18) 64.78 (10.33) 1.01 (0.98 to 1.05, 0.50) -- -- 
IOP, mmHg 22.25 (3.35) 20.79 (2.83) 1.17 (1.02 to 1.34, 0.02) 1.19 (1.04 to 1.36, 0.01) 1.19 (1.03 to 1.38, 0.02) 
CCT, 𝝁m 558.45 (32.49) 555.60 (46.06) 1.00 (0.99 to 1.01, 0.70) -- -- 
TMP, 0 to 4 1.44 (0.82) 1.36 (0.82) 1.13 (0.71 to 1.82, 0.61) -- -- 
Glaucoma 
medication, n 
0.75 (0.91) 1.12 (1.04) 0.68 (0.46 to 1.01, 0.05) 0.63 (0.41 to 0.96, 0.03) 0.63 (0.40 to 1.00, 0.05) 
PGAs users, n  28 (38%) 23 (55%) 0.51 (0.24 to 1.11, 0.09) -- -- 
CAIs users, n  17 (23%) 16 (38%) 0.49 (0.22 to 1.13, 0.09) -- -- 
CAIs: Carbonic anhydrase inhibitors; CCT: central corneal thickness; CI: confidence interval; IOP: intraocular pressure; OR: Odds ratio; 
PGAs: prostaglandin analogues; TMP: trabecular meshwork pigmentation. Data are presented as mean (standard deviation) or number 
(%) in the first two columns. Data were analysed based on complete cases. 
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Model performance 
The final model produced an AUC of 0.68 in the ROC curve (Figure 8). The Hosmer-
Lemeshow goodness of fit test for calibration showed a non-significant discrepancy 
between the number of expected outcomes and the number of observed outcomes with p 
= 0.21(Table 12). Also, the calibration plot showed a satisfied prediction (Figure 9). 
Figure 8: Receiver-operating characteristic (ROC) curve for prediction of success at 
12 months after the laser treatment 
 
 
  
  
 
63 
Table 12: Hosmer-Lemeshow test for calibration of the prediction model for 
treatment success 
Group 
Range of 
probability (%) 
N 
Observed success, 
n (%) 
Predicted success, 
n (%) 
1 19.0 - 40.6 12 6 (50.0) 4.3 (35.7) 
2 41.4 - 49.9 11 4 (36.4) 5.0 (45.8) 
3 52.1 - 57.2 12 4 (33.3) 6.6 (55.0) 
4 58.5 - 62.6 11 9 (81.8) 6.6 (59.8) 
5 63.4 - 66.6 14 7 (50.0) 9.0 (64.5) 
6 67.1 - 69.1 15 10 (66.7) 10.2 (68.3) 
7 70.3 - 71.0 6 5 (83.3) 4.3 (70.9) 
8 71.4 - 76.0 12 11 (91.7) 8.9 (74.4) 
9 77.5 - 80.4 12 8 (66.7) 9.5 (78.9) 
10 81.6 - 91.4 10 9 (90.0) 8.6 (85.8) 
𝜒2 = 10.82, df = 8, p = 0.21 
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Figure 9: Predicted probabilities based on the prediction model and observed 
proportions of individuals with treatment success (intraocular pressure change more 
than 2 mmHg from baseline to the 12-month visit) 
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Chapter 5 Discussion 
 
In this chapter, the findings in this thesis and the comparisons of our outcomes with 
previous studies are described in Section 5.1. In Section 5.2 and 5.3, the strengths and 
limitations are presented and justified. Conclusions and clinical implications are 
summarised in Section 5.4. Finally, Section 5.5 provides some ideas for future studies.  
5.1 Findings 
The main purpose of this thesis was to evaluate the equivalence of IOP reduction effect 
between SLT and ALT for those patients who had previous 360-degree SLT treatment 
while naïve to ALT or glaucoma surgery. Data were extracted from a multicentre 
randomised controlled trial (RCT) registered as “A randomized clinical trial of selective 
laser trabeculoplasty (SLT) in open-angle glaucoma who had been previously treated with 
complete SLT” with an acronym of Repeat Laser Study. The Patients were recruited from 
seven hospitals in different cities across Canada.  
By June 2017, when the data was collected for thesis analyses, 115 patients had finished 
the 12- month follow-up visit without missing data in all the primary and secondary 
outcomes. Over 80% were Caucasian, and the mean age was approximately 65 years with 
a mean baseline IOP of approximately 22 mmHg. The demographic characteristics and 
ophthalmic examinations at baseline were well balanced between the SLT and ALT 
treatment arms as shown in Table 1A and 1B in Chapter 4.  
Efficacy 
The IOP reduction from baseline to 12-month visit was equivalent between the SLT and 
ALT treatment based on either complete case analysis or per-protocol analysis. The mean 
change was 3.35 mmHg (SD 4.96) in the SLT group and 3.36 mmHg (SD 5.06) in the 
ALT group in the 115 complete case cohort (Table 3 in Chapter 4). 
The IOP-lowering outcomes are less than the results presented by Damji et al., who 
reported a mean (SD) IOP decrease of 5.7 (5.63) and 6.0 (4.51) mmHg in the SLT group 
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and the ALT group respectively.61 The study of Damji et al. and the Repeat Laser Study 
both applied laser on 180-degree trabecular meshwork and had comparable baseline 
characteristics of participants. The IOP change in the Repeat Laser Study is also less than 
the meta-analysis outcome reported by Wang et al., whose study summarised the 
outcomes from two randomised clinical trials (RCTs) with meta-analysis.84 The 
synthesized mean IOP reduction at post-laser 12 months was 4.65 mmHg after SLT and 
4.31 mmHg after ALT.84 Both the results of Damji et al. and Wang et al. were obtained 
from laser naïve patients, which may explain some of the discrepancies. In addition, it 
suggests that repeated SLT or ALT based on previous 360-degree SLT is about 50% to 70% 
as efficacious as the primary laser treatment at 12-month follow-up. 
The outcomes of the Repeat Laser Study also demonstrate some difference with other 
studies regarding the efficacy of repeat SLT. In this study, the first SLT was performed 
on 360-degree trabecular meshwork with approximately 100 shots on average while the 
second SLT was applied on 180-degree trabecular meshwork with approximately 50 shots 
on average. In two previous studies, the primary and secondary SLT were both applied on 
360-degree trabecular meshwork with 40 to 60 shots.100 103  These two studies showed a 
mean IOP change after the second SLT was 2.2 mmHg and 4.5 mmHg at about 15 
months respectively.100 103 In the studies of Khouri et al. and Francie et al., approximately 
100 applications on average were performed on 360-degree trabecular meshwork in two 
SLT treatments, and the mean (SD) IOP reduction was 2.9 (5.8) mmHg at 12 months and 
3.4 (3.6) mmHg at 6 to 12 months respectively after the repeat SLT.99 104 The wide range 
of mean IOP change (from 2.2 to 4.5 mmHg) among those studies may be due to different 
baseline characteristics of patients, such as type of glaucoma and baseline IOP. Also, a 
relatively large variance presented in most of the repeat SLT studies may attribute to the 
discrepancy of the mean values. One the one hand, the procedure itself or personal 
characteristics may produce a wide range of outcomes. On the other hand, the fewer shots 
are applied on the trabecular meshwork in each SLT, the less possible for overlap 
between the initial and the second applications, and the efficacy of repeat SLT possibly 
depends on the number of overlap laser shot.   
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Although the mean IOP change was significantly greater in the SLT group than the ALT 
group within 3 months, the equivalence of mean IOP change was seen during 3 to 12 
months shown in Table 3 and Table 4 of Chapter 4. The outcomes of laser success, which 
was defined as an IOP reduction more than 2 mmHg from baseline, were consistent with 
the IOP change shown in Table 5 of Chapter 4.  
The number of medication increased a little on average in both groups, while the 
difference at 12 months between the two groups was not significant (Table 9 in Chapter 
4). One patient (2%) in the SLT group and 4 (7%) in the ALT group received either 
further laser trabeculoplasty or incisional glaucoma surgery during the 12-month follow-
up. Neither the risk difference nor the relative risk of processing to surgery was found a 
significant difference (Section 4.2 in Chapter 4). Those two secondary outcomes both 
suggests a comparable efficacy between SLT and ALT in IOP control within 12 months.  
A series of planned subgroup analyses were conducted, including POAG subgroup, and 
subgroups divided by age, gender, number of glaucoma risk factor, central corneal 
thickness (CCT) at baseline, number of glaucoma medication at baseline, PGAs users, 
CAIs users, and previous SLT time. All those subgroup analyses did not find a significant 
difference between the two laser treatments in IOP change (Table 10 in Chapter 4).  
Safety 
IOP spike was not detected (0%) at post-laser one hour in the Repeat Laser Study 
(Section 4.2 in Chapter 4). Among the previous RCTs comparing SLT and ALT, two 
studies did not detect an IOP spike which requires accurate surgery or an IOP increase ≥
 6 mmHg,58 115 but several studies reported an IOP spike between 4.5% to 15.4% after 
SLT and 3.5% to 17% after ALT.61 110 112 In repeat SLT studies, IOP spike was absent in 
several studies,98 99 121 or had a rate of 2.3% in one study after either the initial or the 
second SLT.101 The outcomes of those repeat SLT studies may indicate that the second 
SLT will not alter the possibility of IOP spike. It was found that IOP spike after laser 
trabeculoplasty was related to high energy level.170 Although IOP spike after laser 
trabeculoplasty is usually transient and resolve spontaneously or with glaucoma 
medication, IOP spike after trabeculectomy has been found to be associated with a long-
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term IOP increase.171 Whether IOP spike predicts a worse outcome of laser 
trabeculoplasty needs further investigations.  
Anterior chamber cell at post-laser 1 hour was mild and ranged from 0 to 2 in the SLT 
group and 0 to 1 in the ALT group (Section 4.2 and Table 7 in Chapter 4). However, 
anterior inflammation was more severe (mean anterior chamber cells 0.51 vs 0.32) and 
happened in more patients (74% vs 64% at one hour; 25% vs 7% at one week) within one 
week after SLT than ALT (Table 7 in Chapter 4). It is in line with the result reported by 
Damji et al.,109 while contrary to those from some other studies.110 112 The inconsistency 
of the comparison of these two lasers can be explained partially by the difference of the 
post-laser steroid treatment schedule and the anterior chamber inflammation examination 
method (subjective or objective). After one month, the percentage of patients who had a 
clear anterior chamber was almost identical between the two groups. Besides, the 
percentage of a trabecular meshwork pigmentation greater than 1 grade was almost 
identical between baseline and 12-month follow-up in both groups (Table 8 in Chapter 4), 
which also suggested an absent or mild post-laser anterior chamber inflammation after 
SLT and ALT. 
The mean best-corrected visual acuity (BCVA) did not have a change larger than 0.1 
LogMAR throughout the study period in both groups (Table 6 in Chapter 4). 
Furthermore, the post-laser visual acuity was comparable between SLT and ALT at all the 
time points. Similarly, the study of Damji et al. did not find a significant change of mean 
BCVA during the follow-up period after SLT or ALT.109 It suggests that laser 
trabeculoplasty is safe in terms of preserving visual acuity compared with incisional 
glaucoma surgeries, which can cause a significant BCVA reduction after surgery.172 173 174 
In summary, SLT had an equivalent IOP reduction effect compared with ALT for patients 
who had previous 360-degree SLT. Complications after SLT or ALT were rare and mild.  
Predictors of laser success 
In this thesis, we set up a prediction model to explore the predictors at baseline for laser 
trabeculoplasty treatment success, which was defined as IOP decrease larger than 2 
mmHg from baseline at 12 months. The covariates were selected from those correlated 
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with the efficacy of SLT or ALT in previous studies. We found only the IOP and the 
number of glaucoma medication used at baseline were significant predictors of success, 
while age, central corneal thickness, trabecular meshwork pigmentation, prostaglandin 
analogues (PGAs), and carbonic anhydrase inhibitors (CAIs) were not significantly 
associated with success (Table 11 in Chapter 4).  
Higher baseline IOP was confirmed to be a strong predictor of treatment success at 12 
months after either univariate or multivariate analysis. For every 4 mmHg elevation of 
baseline IOP, the odds of treatment success were expected to increase 1 time if the 
number of glaucoma medication was constant. The magnitude in this study is within the 
range of the odds ratio (1.12 to 1.58) in numerous studies, including various definitions of 
success and using univariate or multivariate analyses with follow-up time between 1 
month to 12 months.125 126 131 132 134 136 Also, this positive association is in accordance 
with a number of other studies evaluating predictors of IOP-lowering effect of SLT or 
ALT.122 123 124 127 128 129 130 133 135 Since the conventional outflow pathway of aqueous 
humor is pressure dependent, which may explain why higher baseline IOP had a greater 
IOP reduction after laser trabeculoplasty.27 175  
The number of glaucoma medication was found to have a negative association with 
treatment success. The point estimate of odds of laser trabeculoplasty success decreased 
almost 40% for the addition of one glaucoma medication at baseline holding baseline IOP 
fixed. Similarly, Lee et al. found using 3 types of glaucoma medication suggested a 
higher possibility of SLT treatment failure.158 By contrast, some other studies did not find 
an association between the number of glaucoma medication at baseline and IOP reduction 
effect after laser trabeculoplasty.122 123 127 131 132 161  
It is possible that the association between the number of glaucoma drug and laser efficacy 
was confounded by indication.176 One of the possible confounders is the severity of 
glaucoma. Two studies found that pretreatment visual field defect was associated with 
treatment failure after ALT.138 139 However, neither retinal nerve fiber layer thickness126 
nor visual field index123 126, both of which can represent the stage of glaucoma in a certain 
degree, was found to be correlated with the IOP-lowering efficacy of SLT. Therefore, 
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other confounders may exist, such as the structure of trabecular meshwork, which can 
cause the reduction of aqueous humor outflow.5 However, controlling for the indications 
is complicated because some of those confounders are not likely to be quantified, and 
some of them are not available in this study.177  
Other reasons for the disagreement regarding the association between the number of 
glaucoma medication and laser treatment success among studies include differences of 
participant characteristics, definition of laser success, statistics method (linear regression 
model, logistic regression model, or ANOVA), and stopping rule of covariate selection (p 
value) when regression model was developed.  
We did not find an association between age and laser success, while Ayala et al. detected 
a negative correlation between age and time to treatment failure.129 However, many other 
studies also considered that age is not a significant predictor for IOP-lowering effect of 
laser trabeculoplasty.123 131 132 134 136  The opposite conclusion may be due to the mean 
age (76.5 years) of the participants in the study of Ayala et al. being apparently higher 
than the others (57.6 to 69.08 years).  
In addition, baseline CCT was not a significant predictor for laser trabeculoplasty success 
in our study, which is in agreement with many previous studies.122 123 126 131 In opposite to 
those conclusions, Shazely et al. found patients with thinner CCT had a lower percentage 
of IOP reduction after SLT than the thicker ones.150 However, the retrospective study 
used simply a t-test and did not adjust for IOP, which is positive correlated with the 
thickness of central cornea.178 Therefore, the predictive effect of CCT was probably 
confounded by baseline IOP.  
Although we did not find an association between trabecular meshwork pigmentation and 
success, several studies found a higher grade of trabecular meshwork pigmentation had a 
larger IOP reduction after SLT145 153 as well as ALT.139 However, the former two studies 
did not adjust for confounders, such as baseline IOP, which may bias the outcome. 
Therefore, some other studies, all of which used logistic regression model analysis and 
adjusted for potential confounders, drew the same conclusion as ours.131 134 136 146 
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Nevertheless, since most of the studies investigated only SLT, the association between 
trabecular meshwork pigmentation and ALT treatment efficacy need further evaluations. 
Neither PGAs nor CAIs were found correlated to the treatment success in this thesis, 
which is consistent with the conclusions from other studies.122 123 126 132 135 137 147 148 162 
By contrast, some other studies found a positive or negative association between PGAs 
and IOP-lowering effect of SLT.124 128 133 159 160 Whereas this thesis included both SLT 
and ALT patients in the regression model, all those studies evaluated the association 
between PGAs and SLT only. Besides, the statistical method and covariates included in 
the regression model are different from ours. Similarly, two studies found a significant 
association between CAIs and efficacy of SLT.158 161  However, the follow-up period (one 
was 5 years and the other was 1 month) has a huge difference from ours.  
In summary, pre-laser IOP has been found again as the strong predictor of treatment 
success in this thesis. Although the number of glaucoma drug at baseline was found 
negative correlate with success, the association may be due to confounding by indication, 
and the conclusions varied among studies. Therefore, this relationship needs further 
investigation.  
5.2 Strengths of the study 
There are some apparent strengths of this study. First, the data were obtained from an 
ongoing study which was the first registered study comparing SLT and ALT for those 
who had previous 360-degree SLT. The study is a randomised controlled trial, which is an 
optimal design for controlling confounders.  
Second, the participants were recruited from seven cities covering a large geographical 
area across Canada, which provided a generalizable sample of the study. In addition, all 
the physicians are specialists to ensure an adequate surgical skill. Furthermore, the laser 
procedure was standardised in the study protocol. Therefore, the treatment effect was 
expected to be consistent across different surgeons. The two features of the study helped 
increase the external and internal validity of the outcomes. 
  
 
72 
Third, attributed to the double entry procedure, the digital data were reliable since the 
missing value and error rates were low (0.3% and 0.7% respectively) after the comparison 
with the paper records (Appendix 1A and 1 B in Chapter 3).  
Fourth, the rate of withdrawal or lost to follow-up was low with 7 in 128 patients (5%), 
and it was almost balanced in the two treatment groups with 4 (6%) in the SLT group and 
3 (5%) in the ALT group (Figure 2 in Chapter 4). It ensured the validity of the outcome 
analyses.179 
Fifth, we found an equivalent IOP-lowering effect at 12 months between SLT and ALT 
even for those who had received 360-degree SLT before. The equivalence was confirmed 
for both complete cases or per-protocol patients. These outcomes provide a useful 
evidence for clinical decision makes.   
Sixth, we found a significant correlation between IOP or number of glaucoma medication 
at baseline and the efficacy of laser trabeculoplasty (p = 0.01 and 0.03 respectively) 
(Table 11 in Chapter 4). It also provides a meaningful implication for clinical practice.   
5.3 Limitations of the study 
Evaluating equivalence 
First, the sample size was 115, which represented only 84% information of all the 137 
randomised patients. However, after the extreme case analyses, the difference of IOP 
reduction between the two laser groups was found not significant, which indicates that the 
equivalent result is robust.  
Second, we found that some of the patients who had a glaucoma surgery during the 
follow-up period dropped out from the study while some remained in the study. Besides, 
we excluded some of the patients who had missing values for secondary outcomes in the 
complete case analysis. Those may cause some unbalance between the two intervention 
groups and bias the outcomes.  
Third, over 80% of the participants were Caucasian, which may limit the generalization 
of the conclusion to other ethnicity groups.  
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Fourth, although confidence interval approach is informative for testing equivalence, it 
cannot provide a p-value, which is used to determine the strength of evidence to reject the 
null hypothesis.180 
Prediction model 
First, we did not explore all the potential predictors in the original regression model. 
Aqueous humor dynamics, maximum pre-SLT IOP, visual field defect, and diabetes have 
been shown to be significant predictors of laser treatment in some previous studies.134 138 
139 142 147 148 It was because the data of those variables were not recorded or not complete 
in the Repeat Laser Study.  
Second, the backward stepwise method for selecting variables in the prediction model has 
disadvantages, since stepwise methods are known to have some drawbacks. They include 
unstable selection, coefficient estimation bias, misspecification of variability, and 
possible to create a lesser predictive model than a full model.169 
Third, the area under the receiver-operating characteristic curve (AUC) of the prediction 
model for treatment success was 0.68, which suggested the final model was only 
modestly successful in discriminating between the patients who will succeed and those 
who will not succeed.181 In the study of Martow et al.,131 the authors included gender, 
baseline IOP, maximum IOP, previous ALT, trabecular meshwork pigmentation, and type 
of baseline glaucoma eye drop in the multivariate analysis to predict SLT treatment 
success. Baseline IOP was the only significant predictor (p < 0.05) which was kept in the 
model. The AUC of the model was 0.797. Mao et al.134 also performed a multivariate 
analysis with baseline IOP, maximum pre-SLT IOP, trabecular meshwork pigmentation, 
washout of eye drops, and gender as candidate predictors. Both baseline IOP and 
maximum pre-SLT IOP were the significant predictors (p < 0.0001 and p = 0.022) and 
were kept in the model which produced an AUC of 0.72. Those two studies evaluated the 
predictors for the efficacy of primary SLT and produced a larger AUC than ours. It may 
indicate that the efficacy of primary laser treatment is more predictable than repeat laser 
treatment. In addition, the study of Mao et al. suggests that including maximum pre-
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treatment IOP may increase the discrimination ability of the model. However, maximum 
pre-treatment IOP was not documented in the Repeat Laser Study.  
Though some drawbacks were identified in the creation of the prediction model, we have 
to repeat that the primary objective of the Repeat Laser Study and this thesis was to 
confirm the hypothesis that SLT and ALT have an equivalent IOP-lowering efficacy even 
after 360-degree SLT. The sample size and data were determined and recorded based on 
the primary objective. We created a prediction model to explore possible predictors for 
treatment success for this particular group of patients. The significant correlation between 
baseline IOP or number of medications used at baseline and treatment efficacy was 
identified after adjusting for most of the important potential confounders. Therefore, the 
objective of the creation of the prediction model to explore the predictors for the IOP-
lowering effect of laser trabeculoplasty has been achieved. 
5.4 Conclusions and implications 
The industry claims that SLT is repeatable because it does not cause any mechanical 
change of the targeted tissue (mainly refers to the trabecular meshwork).68 However, the 
evidence of the repeatability of SLT is scant.  
In our study, either SLT or ALT after previous 360-degree SLT had a less than 70% of 
the IOP reduction caused by the initial SLT or ALT when the outcomes were compared 
with other studies.61 84 This lowered efficiency was also seen in some studies which 
compared the difference between the primary and repeat SLT, although a significant 
difference was not found in these studies.99 101 121 The different efficacy between the 
primary and repeat laser treatment suggests some irreversible changes of SLT-targeted 
tissue may happen, and those changes can alter the efficacy of the next SLT or ALT.  
Another possibility is that the difference between the primary and repeat laser is owing to 
confounding by indications. For example, the bio-characteristics of the people who failed 
for the primary SLT and those who can maintain a target IOP after the primary SLT may 
be different. Some other confounders such as surgical skill of physicians, demographic 
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characteristics of the patients, etc. can also lead to different outcomes between ours and 
others.  
In addition, a less efficacy of the secondary SLT than the primary SLT suggests that the 
degree of IOP reduction of the third or more SLT will likely be even less beneficial. The 
open-label ongoing study described in Section 5.5 will answer this question. 
The IOP lowering-effect of 180-degree SLT was equivalent to 180-degree ALT in those 
who had 360-degree SLT before. The difference of mean IOP reduction between the two 
treatment groups was -0.01 mmHg (95% CI, -1.86 to 1.84; p = 0.99). Also, the percentage 
of IOP spike at one hour was 0% after the two laser treatments. The difference of mean 
BCVA at 12 months was not significant with p = 0.09. The difference of percentage of 
patients who were free of anterior chamber inflammation at 12 months was almost 
comparable (RD, -0.02 and p = 0.55; RR, 0.98 and p = 0.55). Since the efficacy and 
safety of the two lasers were comparable, when people need a further intervention, some 
other issues can be considered such as the cost, surgical skill, post-laser feelings, etc. 
Regarding the predictors of the efficacy of the laser trabeculoplasty, baseline IOP and 
number of glaucoma medication were two significant predictors for the success of laser 
trabeculoplasty (p = 0.01 and p = 0.03). It suggests that patients who are on maximal 
tolerated medical therapy may not be suitable for laser trabeculoplasty as the next step for 
IOP control, and an incisional surgery should be applied instead. 
5.5 Future studies  
Based on the outcomes of this thesis, some extensions or improvement of the study could 
be considered in the future studies: First, an extension study of the Repeat Laser Study is 
being carried out. It will extend the follow-up time up to 3 years after the laser treatment. 
During the observation period, if the IOP is not controlled under the target level, patients 
will be treated with repeat SLT, another medication, or glaucoma surgery after the 
discussion of the patients and the physicians. In the extension study, on the one hand, the 
long-term comparison between SLT and ALT can be observed. On the other hand, it 
provides an opportunity to evaluate the efficacy of the third or more repeat SLT. Second, 
studies can be designed to evaluate the effect specifically on non-Caucasian. Third, future 
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studies can try to use different predictor selection methods (e.g., Bayesian model average, 
shrinkage of regression coefficients to zero, etc.) and compare the performance of those 
prediction models. 
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Appendices 
Appendix 1A: Errors and missing values found by comparing web-based data and 
paper records for 14 samples available in the Ivey Hospital in June 2017 
Patient ID 12 15 16 17 18 21 
Name of variables Web (paper) Web (paper) 
Web 
(paper) 
Web (paper) Web (paper) 
Web 
(pape
r) 
ACI_Cells_OS   
Visit 2: 
0.5 (1) 
   
ACI_Flare_OD 
Visit 2: 
1 (0.5) 
     
ACI_Flare_OS 
Visit 2: 
1 (0.5) 
     
BCVA_OD (Follow-
up) 
 
Visit 7: 
20/20  
(20/20-1) 
    
BCVA_OS  
(follow-up) 
Visit 2: 
20/15 
( 20/15 -1) 
Visit 3: 
20/20 
(20/20-1) 
  
Visit 3:  
20/20  
(20/20 -2) 
 
BCVA_OS (Baseline)     
20/20  
(20/20 1) 
 
DOB     
1976-10-1 
(1946-10-1) 
 
EyeColour   
Missing 
(brown) 
   
IOP_OD_2 
(Baseline) 
 18 (17)     
IOP_OS_1 
(Baseline) 
 15 (16)     
IOP_OS_2 
(Baseline) 
 17 (16)     
MachineTotalEnergy(
slt_only) 
Missing 
( 52) 
     
ModifiedSchaffer_OD    Visit 7: 3 (4)   
PrevIOP_OD_2  18 (17)     
PrevIOP_OS_1  15 (16)     
PrevIOP_OS_2  17 (16)     
RiskFactors_EthnicBa
ckground 
    
0  
(Asian) 
 
RiskFactors_Myopia      
1  
(0) 
RiskFactors_Other_S
pecify 
  
Missing  
(hyperchol
esterolemia
) 
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Appendix 1B: Errors and missing values after comparing web-based data and paper 
records for 14 samples available in Ivey hospital in June 2017 
Patient ID 22 28 30 34 43 45 51 
Name of 
variables 
Web 
(paper) 
Web 
(paper) 
Web 
(paper) 
Web 
(paper) 
Web 
(paper) 
Web  
(paper) 
Web 
(paper) 
BCVA_OD  
(Follow-up) 
Visit 3: 
20/20 
(20/20 1) 
   
Visit 5: 
20/20  
(20 /20-2) 
Visit 6:  
20/20 (20/25) 
 
BCVA_OS  
(follow-up) 
   
Visit 6: 
20/20 
(20/20 -1) 
Visit 5: 
20/20  
(20/20-2) 
Visit 6:  
20/20 (20/25) 
Visit 4:  
20/20  
(20/20 -2) 
EyeColour 
Blue 
(NA) 
      
Modified 
Schaffer_OD 
    
Visit 7:  
2 (3) 
  
NumberOf 
Applications 
  51 (50)     
PrevIOP 
_OD_1 
   
22  
(no 
record) 
   
PrevIOP 
_OS_1 
   
16  
(no 
record) 
   
Stop_Month  
of therapy 
 
Alrex: 
Missing 
(9) 
   
Altace: 
Missing (11); 
Hydrochlorothiazide: 
Missing (11); 
Zyloprim:  
Missing (11) 
 
Stop_Year  
of therapy 
 
Alrex: 
Missing 
(2013) 
   
Altace: 
Missing (2014); 
Hydrochlorothiazide: 
Missing (2014); 
Zyloprim: 
Missing (2013) 
 
TMP_OD   3 (2)     
TMP_OS   3 (2)     
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Appendix 2A: Actions for errors and missing values of 137 patients who were recruited in the study and documented by June 
2017 
Table name BASELINECLINICALEXAM BASELINECLINICALEXAM ELIGIBILITYASSESSMENT 
Variable name bcva_od bcva_os oag_* 
Main ID Visit id  original modification original modification original modification 
19 1 40 20/20 40 20/20   
27 1     missing POAG (corrected by study coordinator) 
32 1 20/20 -1 20/20     
100 1   20.30 20/30   
101 1 20 20/20 20-1 20/20-1   
104 1 20/' 25 20/25     
105 1 20/'30 20/30 20/'30 20/30   
127 1   20.30-2 20/30-2   
134 1   2025 20/25   
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Appendix 2B: Actions for errors and missing values of 137 patients who were recruited in the study and documented by June 
2017 
Table name MEDICATIONSTHERAPIES FOLLOWUPEXAM FOLLOWUPEXAM 
Variable name ocular medication label bcva_od bcva_os 
Main ID Visit id  original modification original modification original modification 
15 1 alrex labeled as non-ocular labeled as ocular     
23 2   20 20/20   
28 7 alrex labeled as non-ocular labeled as ocular     
48 5     2-/20-2 20/20-2 
77 2   2040 20/40   
82 6     20/'20 20/20 
83 6     20/'40 20/40 
84 4     2-/30-1 20/30 
89 1 Acuvail labeled as non-ocular  labeled as ocular     
92 1 
preforte and  Zymar labeled as 
non-ocular 
labeled as ocular     
101 2     20/'25 20/25 
104 2     20/'30 20/30 
105 2   20/'40 20/40   
115 6     20.16-2 20/16-2 
128 6   20-/20-1 20/20-1   
150 1   535 no   
153 5     20?25+1 20/25 
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Appendix 2C: Actions for errors and missing values of 137 patients who were recruited in the study and documented by June 
2017 
Table name FOLLOWUPEXAM FOLLOWUPEXAM FOLLOWUPEXAM 
Variable name TMP  aci_flare_od  aci_cells_od  
Main ID Visit id  original modification original modification original modification 
29 1   missing no   
47 1   missing no   
134 1 missing no     
110 5     missing no 
157 5   missing no missing no 
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Appendix 2D: Actions for errors and missing values of 137 patients who were recruited in the study and documented by June 
2017 
Table name MEDICATIONSTHERAPIES MEDICATIONSTHERAPIES 
Variable name start_year (medication) start_month (medication) 
Main ID Visit id  original modification original modification 
28 7     
89 1  Simbrinza , Systane, Balance were recorded as 16 2016   
106 1   missing for Azopt November (corrected  by study coordinator) 
146 1 29 2009   
148 1 Alphagen was recorded as 16 2016   
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Appendix 2E: Actions for errors and missing values of 137 patients who were recruited in the study and documented by June 
2017 
Table name Mergetable Mergetable Mergetable 
Variable name riskfactors_age riskfactors_ethnicbackgroud Treatmenttime 
MainID original modification original modification original modification 
90   0 1   
129   0 1   
128   0 1   
15 0 1      
18 0 1      
25 0 1      
26 0 1      
31 0 1      
32 0 1      
67 0 1      
72 0 1      
90 0 1      
114 0 1      
119 0 1      
128 0 1      
156 0 1       
141     12:20  No (not related to outcome analyses) 
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Appendix 3: Number of errors and missing values found by June 2017 in the digital data sets of 137 patients 
Inclusion criteria (n=137) Number of deviation of inclusion criteria (%) 
IOP > 16 mmHg in two consecutive visit separated at least one month 14 (10%) 
BCVA > 20/200 for two eyes 1 (0.7%) 
  
Exlusion criteria (n=137) Number of patients who violated exclusion criteria (%) 
Anticipated intraocular surgery in the 12 months N/A 
Corneal disease  N/A 
Systematic or topical steroids used at baseline 5 (4%) 
Systematic steroids anticipated in the 6 months following treatment N/A 
  
Logic and consistency check (n=137) Number of inconsistent records (%)  
Riskfactor (age > 60) 13 (9%) 
Riskfactors (not Caucasian) 3 (2%) 
IOP 1-hour follow-up time earlier than laser treatment time  1 (0.7%) 
  
Error or missing in medication records  N (%) 
Ocular medications labeled as non-ocular medications (n=414 records) 5 (1%) 
Missing start year (non-ocular medication) (n=382 records) 4 (1%) 
Missing start month  (non-ocular medication) (n=382 records) 146 (38%) 
Missing stop month when stop year is not missing (non-ocular medication) 
(n=382 records) 
1 (0.3%) 
Missing start year (ocular medication) (n=414 records) 6 (1%) 
Missing start month  (ocular medication) (n=414 records) 20 (5%) 
Missing stop month when stop year is not missing (ocular medication) (n=414 
records) 
3 (0.7%) 
  
Missing of laser treatment time (n=137) 16 (12%) 
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